



---

## ESSENTIAL MEDICINE LIST- 2018

---

---

Maldives Food and Drug Authority,  
Medicine and Therapeutic Goods Division  
Republic of Maldives

---



Foreword by Minister of Health



Essential Medicines include all medicines required to satisfy the health care need of the population. In a functioning health system, quality assured and safe essential medicines should be available to the public from public health care facilities in adequate and rationale amounts with affordable cost-effectiveness.

Since Maldives imports pharmaceuticals for the Maldivian market, the purpose of national essential medicine list is to face the challenges faced in the quality and safety of pharmaceuticals available in the market and to ensure that there is a continuous supply of pharmaceuticals available. Furthermore, through this list it can be ensured that essential medicines are rationally used and also accommodate the increasing needs for accessing the medicines. The system also requires registered importers for the import of essential medicines, which can guarantee that there is an uninterrupted supply of the listed essential medicines.

The essential Medicine List is a result from the commitment of the responsible team. I would like to take this opportunity to sincerely thank the core committee for their valuable oversight and technical guidance they have provided in revising for this publication. Lastly, I would like to show my gratitude and appreciation for the staff of MFDA for finalizing the list for publication.

I believe through this publication the Maldivian health care system will be directed towards a more effective system that has the ability to resolve the concerns and issues faced in the provision of vital health care.

Thank You

A handwritten signature in blue ink, appearing to read "Abdulla Nazim Ibrahim".

Abdulla Nazim Ibrahim

Minister of Health

Essential Medicine List 2018

Approved By:



Shareefa Adam Manik

Director General

Maldives Food and Drug Authority

Endorsed by:



Khadeeja Abdul Samad Abdulla

Permanent Secretary

Ministry of Health

PUBLISHED BY:

Maldives Food and Drug Authority (MFDA)

Ministry of Health

Male', Republic of Maldives

## Contents

I.	Introduction .....	5
II.	Why essential medicine list?.....	5
III.	History and importance of EML .....	5
IV.	Revision process for EML 2018 & members of the revision core committee and specialists who assisted in revising the EML 2018 .....	6
V.	General categorization of EML according to levels of care .....	8
	P, S, and T:.....	8
	S:.....	8
	T: .....	8
	Sp: .....	8
	NP:.....	8
VI.	Categorization of antibiotics .....	8
	ACCESS Group: .....	9
	WATCHED Group: .....	9
	RESERVED group: .....	10
VII.	Implementation of EML 2018 .....	10
VIII.	Explanation of dosage forms .....	11
	A. Principal dosage forms used in EML – Oral administration.....	11
	B. Principal dosage forms used in EML – parenteral administration.....	12
	C. Other dosage forms .....	13
X.	Essential Medicines List 2018 (Total).....	14
XI.	Essential Medicine List 2018 (with Classifications).....	32

## I. Introduction

Essential medicines are those that are deemed to address the health care needs of the population and that shall be available at the appropriate dosage forms and strengths at all times. They reflect the needs based on the disease burden of a particular country. The medicines listed in the essential medicine list shall be available at specified levels of healthcare system, they are selected based on their proven safety, clinical efficacy, and affordable cost and assured quality. Essential Medicine List (EML) 2018 is the result of review and revision of the earlier 2016 version, which reflects the needs of the population in Maldives from the primary to tertiary and specialist, cares facilities. The list also accommodates the needs for medicines from the national health program.

## II. Why essential medicine list?

With so many medicines available in the world market, it would not be possible to supply all of those medicines into the health care system. With too many medicines to choose, the prescribers may also have challenges in keeping up to date and in making decision on the best treatment alternative for patients, which may lead to a kind of inconsistency prescribing practices. The financial resources for medicines are never unlimited to cover all variety of medicines in the market, where many of those medicines are often considered as non-essential. Therefore, the rationale for selection of essential medicines is that it would lead to better access and availability, more rational use by prescribers and lower cost to the system. Without EML, it would not be possible to provide a consistent access to the needed medicines for those in need. Obviously the implementation of EML would contribute significantly to the success of the universal health coverage (UHC) policy.

## III. History and importance of EML

The concept of essential medicines was first introduced by the World Health Organization in 1977 followed by the adoption and implementation of the concept by many countries, non-governmental organizations and international nonprofit supply agencies. The list consists of the most effective medicines for specific indications. It is compiled according to the healthcare requirements of the majority of the population. Such a careful selection of a limited range of essential medicines leads to better quality of healthcare, more efficient management of medicines and more cost effective use of health resources.

EML concept is accepted globally and is considered as one of the important milestone in public health in ensuring equal access to the needed medicines, both in developed and developing countries. Nowadays

## **Essential Medicine List 2018**

more than one hundred and sixty (160) countries have adopted the concept and use their national EML as a basis for medicine supply, medicine reimbursement and medicine use by prescribers.

The EML guides the policies set up by hospital on medicines, medicine procurement and supply in the public sector, medicines reimbursement by health insurance, and also medicines donations. EML also assists the quantification and price calculation of medicines. It can be used as a reference document in the process of medicines prescribing. Hence, the use of medicines in the EML is expected to improve prescribing practices as well as improving access, health services and ultimately health outcomes. The appropriate use of medicines selected in the EML promotes rational use of medicines, especially antimicrobials, which in turn it would also reduce the risk of developing antimicrobial resistance.

Maldives Essential Medicines List was first developed in 2009 and subsequently revised in 2013 and 2016 to accommodate the changes on the healthcare needs and the introduction of new medicines, especially for the national health program. The medicines included in the current EML, reflect the current health care needs of the Maldives population. The Maldives Food and Drug Authority is responsible to ensure the quality of medicine included in the EML 2018.

### **IV. Revision process for EML 2018 & members of the revision core committee and specialists who assisted in revising the EML 2018**

The revision of the EML 2016 was undertaken by a core committee appointed by the Maldives Food and Drug Authority, and assisted by an expert from the World Health Organization. The Core committee was selected from the MFDA Board, representing clinical specialists, medicines regulators, health program, regional Atoll Health Authorities and referral hospitals. The core committee reviewed the proposition for deletion and addition into the EML 2018. The propositions for addition and deletion were received by MFDA from different departments, health program, hospitals and Atoll Health Authority. The review was based on agreed criteria on medicines safety, clinical efficacy, affordable cost, suitability to the healthcare system and their availability for Maldives. There are forty one (35) deletions and thirty (30) additions, and altogether there are four hundred and thirty four (440) medicines (excluding repetitions) listed in the EML 2018.

## Essential Medicine List 2018

The WHO consultant, Mr. Budino Santoso worked with the committee throughout the EML finalization.

The core committee members are as follows:

No	Names	Designation
1	Dr. Niyasha Ibrahim (Chairperson)	Head of Child Health Department, Indira Gandhi Memorial Hospital
2	Dr. Thasneem Faroog	Consultant in Obstetrics and Gynecology, Indira Gandhi Memorial Hospital
3	Dr. Ahmed Migdhaad	Physician, Internal Medicines, Indira Gandhi Memorial Hospital
4	Ms. Aishath Mohamed	Deputy Director General, Pharmaceuticals Maldives Food and Drug Authority

Apart from these specialists in the core committee the following specialists and experts also contributed to the EML finalization.

1	Ms. Shareefa Adam Manik	Director General, Maldives Food and Drug Authority
2	Dr. Mohamed Shifan	Consultant Surgical Oncologist Indira Gandhi Memorial Hospital
3	Dr. Nazla Rafeeq	Health Protection Agency, Ministry of Health
4	Dr. Mariyam Jenyfa	Health Protection Agency, Ministry of Health

Secretariat work was done by:

1	Mr. Mohamed Fazeen	Maldives Food and Drug Authority
2	Ms. Fathimath Azla	Maldives Food and Drug Authority

## V. General categorization of EML according to levels of care

Based on the levels of care, the medicines included in the EML 2018, have been categorized as follows:

**P, S, and T:** Denotes essentially at Primary, Secondary and Tertiary levels respectively. This indicates essentiality at all the levels of health care. Hence the medicines categorized in this level shall be available in all levels of health care system. This category includes health facilities such as health centers, atoll hospitals, regional hospitals and Tertiary hospitals (IGMH and ADK).

**S:** Denotes the essentiality at secondary and tertiary level respectively, like atoll and regional hospitals and Tertiary hospitals (IGMH and ADK).

**T:** Denotes the essentiality at tertiary level, the Indira Gandhi memorial hospital (IGMH) and ADK hospital

**Sp:** Denotes the essentiality of the particular medicine for specialist use. These medicines should be available and are to be used in health facilities where the concerned specialist is available and the medicine is to be used under the specialist's instruction or guidance.

**NP:** Denotes the medicines used for the National programs like TB, malaria etc. These medicines should be available as required by the national programs, in public health units of all levels of health care.

## VI. Categorization of antibiotics

There are thirty two (32) antibiotics in the EML 2018, and they are categorized in line with the new categorization of the World Health Organization. The WHO Expert Committee on the Selection and Use of Essential Medicines 2017 has devised a new categorization for antibiotics. Depending on their needs for access, their potentials for microbial resistance and their reserved use, antibiotics are categorized into different groups which include ACCESS, WATCHED and RESERVED Groups.

This categorization is aimed to maximize the benefits of antibiotics in treating infections for which they are indicated, to minimize the risk of resistance for antibiotics with high potential of resistance and to sustain the clinical efficacy of antibiotics which only be used for very specific infection where no other alternative is available. Every effort is to be taken to ensure their availability, appropriate distribution and rational usage in order to maximize the benefits and to minimize the risk of resistance. The categorization of antibiotics in the EML 2018 is as follows.

**ACCESS Group:** The group includes antibiotics which are recommended for empiric, first and second choice treatment options for common infections. These antibiotics should be widely available, at an affordable cost and in appropriate formulation and of assured quality.

Below mentioned is the ACCESS group of antibiotics:

Beta-lactam medicines		Other antibacterial	
amoxicillin	cefotaxime*	amikacin	doxycycline
amoxicillin + clavulanic acid	ceftriaxone*	erythromycin	gentamicin
ampicillin	Flucloxacillin	chloramphenicol	metronidazole
benzathine benzylpenicillin	piperacillin + tazobactam*	ciprofloxacin*	nitrofurantoin
benzylpenicillin	procaine benzyl penicillin	clarithromycin*	sulfamethoxazole + trimethoprim
cefixime*	Penicillin		<i>vancomycin (parenteral)*</i>

**WATCHED Group:** This group of antibiotics includes those which are generally having higher potential for resistance but are still recommended for first or second choice treatment for a limited number of conditions. The group also includes highest priority agents on the list of Critically Important for Human Medicines. The use of these antibiotics should be monitored and become the target for antibiotics stewardship program. Antibiotics in this group include:

Below mentioned is the WATCHED group of antibiotics:

Quinolones and fluoroquinolones e.g. ciprofloxacin
3rd-generation cephalosporins (with or without beta-lactamase inhibitor) e.g. cefixime, ceftriaxone, cefotaxime, ceftazidime, cefuroxime
Macrolides e.g. azithromycin, clarithromycin
Glycopeptides e.g. vancomycin
Anti-pseudomonal penicillins with beta-lactamase inhibitor e.g. piperacillin + tazobactam
Carbapenems e.g. meropenem

**RESERVED group:** Antibiotics in this group should be used as the “last resort options”, tailored to highly specific patients and settings, and when other alternatives have failed. They should become the priority target for antibiotics stewardship program, and their utilization should be monitored and reported.

Below mentioned is the RESERVE group of antibiotics:

**Amphotericin**

**Colistin**

**Polymixin**

**Vancomycin**

The availability of antibiotics belonging to ACCESS group and the use and distribution of antibiotics belonging to WATCHED and RESERVED GROUP needs to be monitored from time to time.

## VII. Implementation of EML 2018

EML 2018 should serve as a basis for medicines supply and availability at health facilities and pharmacies, as a basis for medicines reimbursement by AASANDA health insurance and as guides for prescribing. It is part of the public obligation of relevant stakeholders, like STO pharmacies, to ensure the supply and availability of medicines listed in the EML 2018 at the healthcare facilities and pharmacies.

The implementation of EML 2018, should include effective actions for advocacy and promotion amongst stakeholders in order (1) to improve understanding, acceptance and compliance to Essential Medicines List, (2) to improve access, supply, availability of good quality essential medicines in health facilities and public pharmacies, and (3) better rational use of medicines with better health outcome.

The availability of essential medicines at health facilities, their rational usage and the compliance to EML 2018, and their economic implication on medicines financing and reimbursement, should be monitored using relevant indicators from time to time. Any gaps pertaining to their availability and supply at health facilities or pharmacies, their appropriate usage, and their economic implication on medicines expenditures need to be identified and addressed appropriately by relevant authority & stakeholders.

Implementation of EML 2018 is a multidisciplinary undertaking, where communication, collaboration and coordination between different authorities/stakeholders are of critical importance. A mechanism for communication, collaboration and coordination for improving access to essential medicines and their rational usage is to be initiated through regular forum meeting. MFDA would serve as secretariat and coordinator for this forum for communication, collaboration and coordination.

### VIII. Explanation of dosage forms

The main terms used for dosage forms in the Essential Medicines List is detailed below with the reference to WHO essential medicine list.

#### A. Principal dosage forms used in EML – Oral administration

Term	Definition
Solid oral dosage form	Refers to tablets or capsules or other solid dosage forms such as 'melts' that are immediate-release preparations. It implies that there is no difference in clinical efficacy or safety between the available dosage forms, and countries should therefore choose the form(s) to be listed depending on quality and availability. The term 'solid oral dosage form' is <i>never</i> intended to allow any type of modified-release tablet.
Tablets	Refers to: Uncoated or coated (film-coated or sugar-coated) tablets that are intended to be swallowed whole; Un-scored and scored*; Tablets that are intended to be chewed before being swallowed; Tablets that are intended to be dispersed or dissolved in water or another suitable liquid before being swallowed; Tablets that are intended to be crushed before being swallowed.  The term 'tablet' without qualification is <i>never</i> intended to allow any type of modified-release tablet.
Tablets (qualified)	Refers to a specific type of tablet: chewable - tablets that are intended to be chewed before being swallowed; dispersible - tablets that are intended to be dispersed in water or another suitable liquid before being swallowed; soluble - tablets that are intended to be dissolved in water or another suitable liquid before being swallowed; crushable - tablets that are intended to be crushed before being swallowed; scored - tablets bearing a break mark or marks where sub-division is intended in order to provide doses of less than one tablet;

	<p>Sublingual - tablets that are intended to be placed beneath the tongue.</p> <p>The term 'tablet' is <i>always</i> qualified with an additional term (in parentheses) in entries where one of the following types of tablet is intended: gastro-resistant (such tablets may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.</p>
Capsules	<p>Refers to hard or soft capsules.</p> <p>The term 'capsule' without qualification is <i>never</i> intended to allow any type of modified-release capsule.</p>
Capsules (qualified)	<p>The term 'capsule' with qualification refers to gastro-resistant (such capsules may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.</p>
Granules	<p>Preparations that are issued to patient as granules to be swallowed without further preparation, to be chewed, or to be taken in or with water or another suitable liquid.</p> <p>The term 'granules' without further qualification is <i>never</i> intended to allow any type of modified-release granules.</p>
Oral powder	<p>Preparations that are issued to patient as powder (usually as single-dose) to be taken in or with water or another suitable liquid.</p>
Oral liquid	<p>Liquid preparations intended to be <i>swallowed</i> i.e. oral solutions, suspensions, emulsions and oral drops, including those constituted from powders or granules, but <i>not</i> those preparations intended for <i>oromucosal administration</i> e.g. gargles and mouthwashes.</p> <p>Oral liquids presented as powders or granules may offer benefits in the form of better stability and lower transport costs. If more than one type of oral liquid is available on the same market (e.g. solution, suspension, granules for reconstitution), they may be interchanged and in such cases should be bioequivalent. It is preferable that oral liquid does not contain sugar and that solutions for children do not contain alcohol.</p>

#### B. Principal dosage forms used in EML – parenteral administration

Term	Definition
Injection	Refers to solutions, suspensions and emulsions including those constituted from powders or concentrated solutions.
Injection (qualified)	Route of administration is indicated in parentheses where relevant.
Injection (oily)	The term 'injection' is qualified by '(oily)' in relevant entries.
Intravenous infusion	Refers to solutions and emulsions including those constituted from powders or concentrated solutions.

### C. Other dosage forms

Mode of administration	Term to be used
To the eye	Eye drops, eye ointments.
Topical	For liquids: lotions, paints. For semi-solids: cream, ointment.
Rectal	Suppositories, gel or solution.
Vaginal	Pessaries or vaginal tablets.
Inhalation	Powder for inhalation, pressurized inhalation, nebulizer

### IX. Code

P,S,T	To be available and used in Primary, Secondary and Tertiary level of care
S,T	To be available and used only in Tertiary and secondary level of care
T	To be available and used only in Tertiary level of care
NP	Medicine used in Public Health National programs only
SP	Should be used by / under instruction of a Specialist
NP, T	Medicine used in Public Health National programs only To be available and used only in Tertiary level of care
NP, Sp	Medicine used in Public Health National programs only Should be used by / under instruction of a Specialist

## X. Essential Medicines List 2018 (Total)

#	Levels	Medicine	Dosage Form and Strength
1	NP	Abacavir (ABC)	Oral liquid: 100 mg (as sulfate)/5 ml., Tablet: 300 mg (as sulfate)
2	S,T	Acarbose (starch, microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide)	Tablet: 25mg, 50mg, 100mg
3	S,T	Acetazolamide	Tablet:250 mg
4	P,S,T	Acetyl salicylic acid	Tablet:75mg, 100mg, 150 mg, 300mg
5	S,T	Acyclovir	Cream: 3% ,5%; Ointment: 5%; Injection: 250mg (as sodium salt) in vial; Tablet: 200 mg, 400mg , 800 mg, Syrup: 200mg/5ml
6	S,T	Adenosine	Injection: 3mg/ml in physiological saline in 2ml ampoule
7	P,S,T	Adrenaline	Injection:1mg/ml (1 in 1000 ) , 0.5mg/ml (1 in 10,000)
8	P,S,T	Albendazole	Oral liquid: 200mg/5ml, Tablet: 200mg, 400 mg
9	Sp	Albumin	Injection :5% and 20%
10	S,T	Alendronate	Tablet: 35mg, 40mg, 70mg
11	T	Alfacalcidol	Tablet:0.25mg,
12	S,T	Allopurinol	Tablet:100 mg
13	P,S,T	Alprazolam	Tablet: 0.25 mg, 0.5mg
14	S,T	Alteplase	Injection: 20mg, 30mg, 50mg
15	P,S,T	Aluminium-Magnesium based antacid	Tablet: 200mg + 200mg,400mg + 400mg (hydroxide); Oral liquid: 40mg/ml+ 40mg/ml
16	Sp	Amidotrizoate (urograffin 60%, 76%)	Injection: 140-420 mg iodine (as sodium or meglumine salt)/ml in 20-ml ampoule
17	S,T	Amikacin sulphate (ACCESS Group)	Injection: 250 mg in 2ml aqueous solution in vial for paediatric use; Powder for injection: 1000 mg in vial
18	Sp	Amino Acid	Infant solution: 10% (TPN)
19	Sp	Aminophylline	injection: 25mg/ml in 10ml ampoule
20	S,T	Amiodarone	Injection:50mg/ml in 10ml, Tablet: 100mg, 200mg
21	P,S,T	Amitriptyline	Tablet: 10mg, 25 mg (hydrochloride)
22	P,S,T	Amlodipine	Tablet: 2.5mg, 5mg
23	P,S,T	Amoxicillin (ACCESS Group)	Capsule or Tablet; 250 mg, 500 mg (anhydrous), Powder for oral suspension:125 mg (anhydrous)/5 ml

24	P,S,T	Amoxicillin + clavulanic acid (ACCESS Group)	Oral liquid: 156.25mg/5ml (125mg+31.25mg/5ml), 312.5mg/5ml (250mg+62.5mg/5ml), 228.5mg/5ml, (200mg+28.5mg/5ml) , 278.5mg/5ml (250mg+28.5mg/5ml); Tablet: 625mg, 375mg; 62.5mg/ml; Oral drops Powder for injection: 600 mg, 1.2 g in vial
25	S,T	Amphotericin B	Injection:50mg/vial ( conventional or liposomal complex)
26	P,S,T	Ampicillin (ACCESS Group)	Powder for injection: 500 mg, 1 g (as sodium salt) in vial; Tablet: 500 mg
27	S,T	Anti-D immunoglobulin (human)	Injection: 300 micrograms in single-dose vial
28	P,S,T	Anti-tetanus immunoglobulin (human)	Injection: 250 IU ,500IU
29	NP	Artemether	Tablet: 80 mg, Injection: 80 mg
30	NP	Artesunate	Tablet: 150 mg , Injection: 150 mg
31	P,S,T	Ascorbic acid	Tablet:500 mg
32	Sp	Atomoxetine	Tablet / capsules: 10mg,18mg, 25mg
33	P,S,T	Atorvastatin	Tablet: 5mg,10 mg, 20mg
34	S,T	Atracurium	Injection: 10 mg/ml
	P,S,T	Atropine sulphate	Injection: 0.6 mg in 1-ml ampoule
35	S,T	Atropine sulphate	Injection: 0.6 mg,1mg (sulfate) in 1-ml ampoule
36	T	Azathioprine	Tablet: 50 mg
37	S,T	Azithromycin (WATCHED Group)	Tablet: 250 mg, 500mg, 1000mg , Oral liquid: 100g/5ml (for restricted indications only), Injection: 500 mg
38	S,T	Baclofen	Tablet: 10mg
39	Sp	Barium sulfate	Aqueous suspension/powder
40	NP	BCG vaccine	
41	P,S,T	Beclometasone	Inhalation (aerosol): 50 micrograms per dose (dipropionate); 250 micrograms (dipropionate) per dose; Solution (nasal Spray)
42	P,S,T	Benzathine benzylpenicillin (ACCESS Group)	powder for injection: 1.44 g benzylpenicillin (=2.4 million IU), in 5-ml vial, 1.2million IU
43	S,T	Benzoyl peroxide	Lotion and gel: 2.5% , 5%
44	P,S,T	Benzyl benzoate	Lotion: 25%

45	P,S,T	Benzylpenicillin (ACCESS Group)	Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium salt) in vial
46	Sp	Betamethasone	Injection:6mg/ml
	P,S,T	Betamethasone	Ointment / cream: 0.1%,0.05% (as dipropionate)
47	P,S,T	Bisacodyl	Tablet: 5 mg , Suppository: 10mg
48	P,S,T	Blood	Whole blood and packed cells
49	S,T	Bromocriptin	Tablet: 2.5mg 5 mg
50	S,T	Bupivacaine	Injection for Spinal anesthesia : 0.5% (hydrochloride) in 4-ml ampoule with 7.5% glucose solution, Injection: 0.25%,0.5% (hydrochloride) in vial
51	S,T	Cabergoline	Tablet: 0.25mg, 0.5mg
52	Sp	Caffeine Citrate	Injection 20mg/ml ( equivalent to 10mg caffeine base/ml ); Oral liquid 20mg/ml (equivalent to 10mg caffeine base/ml )
53	P,S,T	Calamine	Lotion
54	S,T	Calcium gluconate	Injection:100mg/ml in 10 ml ampoule
55	T	Capecitabine	Tablet: 150 mg; 500 mg
56	P,S,T	Carbamazepine	Oral liquid: 100mg/5ml; Tablet (scored): 100mg, 200mg
57	P,S,T	Carbimazole	Tablet (film coated): 5 mg , 10mg
58	T	Carboplatin	Injection: 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL
59	S,T	Carvedilol	Tablet: 3.125mg, 6.25mg
60	T	Cefadroxil	Tablet: 250mg, 500mg, Syrup: 125mg/5ml
61	T	Cefazolin	Injection: 500mg, 1gm
62	P,S,T	Cefixime (WATCHED Group)	Tablet 100mgDT, 200mg,400mg; Syrup: 50mg/5ml
63	S,T	Cefotaxime (WATCHED Group)	Injection: 250mg, 500 mg, 1g
64	S,T	Ceftazidime (WATCHED Group)	Powder for injection: 250 mg (as pentahydrate) in vial
65	S,T	Ceftriaxone (WATCHED Group)	Injection: 250mg, 1 g
66	S,T	Cefuroxime (WATCHED Group)	Injections: 250 mg, 500 mg; Tablets: 125 mg, 250 mg (as cefuroxime axetil)
67	P,S,T	Cetirizine	Oral liquid: 5mg/ml, Tablets: 10 mg
68	P,S,T	Charcoal activated	Powder, 50g cans or packs
69	T	Chloral Hydrate	Syrup: 250mg/5ml
70	P,S,T	Chloramphenicol	Solution (eye drops): 0.5%, Ointment: 1%

	S,T	Chloramphenicol (ACCESS Group)	Capsules: 250mg, Oral suspension: 150mg (as palmitate) /5ml, Powder for injection 1g (sodium succinate)/ml in 2-ml I ampoule.
71	S,T	Chlordiazepoxide	Tablet: 10mg
72	P,S,T	Chlorhexidine	Solution: 5%
73	P,S,T	Chlorine base compound	Powder: (0.1% available chlorine) for solution
74	NP	Chloroquine	Tablet:150 mg
75	P,S,T	Chlorozelenol (dettol)	Cream: 4.8%
76	P,S,T	Chlorpheniramine maleate	Injection: 10 mg (hydrogen maleate) in 1-ml ampoule, Oral liquid: 2 mg/5 ml, Tablet: 4 mg (hydrogen maleate)
77	P,S,T	Chlorpromazine	Oral liquid: 25 mg (hydrochloride)/5ml, Tablet: 100 mg (hydrochloride)
78	T	Cholecalciferol	Granules/sachets
79	Sp	Cholera vaccine	
80	P,S,T	Cinnarazine	Tablet: 5 mg,25mg
81	P,S,T	Ciprofloxacin (WATCHED Group)	Solution eye/ear drops 0.3%; eye ointment 0.3%; Eye drops; Tablet: 250 mg,500mg (as hydrochloride)
82	T	Cisplatin	Injection: 50 mg/50 mL; 100 mg/100 mL.
83	S,T	Clarithromycin (WATCHED Group)	Tablets: 250mg; 500 mg (for restricted indications only)
84	NP	Clofazimine	Capsule: 50 mg, 100 mg
85	S,T	Clomiphene	Tablet: 25mg,50 mg, 100mg (citrate)
86	T	Clomipramine	Capsules: 10 mg, 25 mg (hydrochloride)
87	S,T	Clonidine	Tablet: 75mcg,100mcg ,150mcg
88	P,S,T	Clopidogrel	Tablets:75 mg
89	P,S,T	Clotrimazole	Vaginal Tablets: 100mg, 200mg; Gel : 1%, 10 %; Cream; solution (ear drops); Oral paint
90	P,S,T	Clotrimazole + Betamethasone	Cream: 0.025% + 1%,
91	P,S,T	Clotrimazole + hydrocortisone	Solution ( ear drops)
92	S,T	Clozapine	Tablet 25 mg - 200 mg
93	P,S,T	Coal tar	Lotion
94	S,T	Colistin (RESERVED group)	Injection: 150mg/vial
95	P,S,T	Condoms	
96	Sp	Copper-containing device	IUCD ( CopperT 380)
97	Sp	Cryoprecipitate	Injection
98	T	Cyclopentolate	Eye drops 1%

99	T	Cyclophosphamide	Powder for injection: 500 mg in vial; 25mg Tablet:
100	NP	Cycloserine	Capsule or tablet: 250 mg
101	T	Cyclosporin	Capsule: 25 mg, Injection 50 mg/ml
102	NP	Daclatasvir	Tablet: 90mg
103	P,S,T	Danazol	Tablet: 100mg, 200mg
104	T	Dantrolene Sodium	Injection: 20mg
105	NP,T	Dapsone	Tablet: 25 mg, 50 mg, 100 mg
106	P,S,T	Deferasirox	Tablet:125mg, 250mg , 500mg
107	P,S,T	Deferiprone	Tablet:500mg
108	P,S,T	Desferrioxamine	Injection: 500 mg/ml (mesylate) in ampoule
109	Sp	Dexamethasone	Injection: 4mg dexamethasone phosphate (as disodium salt) in 1-ml ampoule;
	S,T	Dexamethasone	Injection: 4mg as disodium salt in 1ml ampoule , Tablets: 0.5mg
	P,S,T	Dexamethasone	eye drops
	P,S,T	Dexamethasone	Injection: 4 mg dexamethasone phosphate (as disodium salt) in 1-ml ampoule
110	Sp	Dextran	Injectable solution: Dextran 40, dextran 70
111	P,S,T	Diazepam	Injection: 5 mg/ml in 2-ml ampoule intravenous. Rectal solution and suppository; Tablet (scored): 2mg, 5mg, 10mg; Syrup: 2mg/5ml
112	P,S,T	Diclofenac sodium	Injection: 25 mg/ml in 3-ml ampoule, Tablet: 25mg,50mg enteric coated, Suppository:12.5mg, 50mg
113	NP	Diethylcarbamazine	Tablet: 50 mg,100 mg
114	P,S,T	Digoxin	Injection: 250 micrograms/ml in 2-ml ampoule Oral solution: 50 micrograms/ml Tablet: 62.5 micrograms, 250 micrograms
115	S,T	Diltiazem	Injection: 25mg/5ml, Ointment:2%
116	P,S,T	Diosmine + Hisperidine	Tablet :500mg
117	NP	Diphtheria + Tetanus	
118	NP	Diphtheria, pertussis, tetanus vaccine	
119	NP	Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B- Homophiles influenza type b	
120	Sp	Dobutamine	Injection 250mg/5ml
121	T	Docetaxel	Injection 20 mg/ mL; 40 mg/ mL
122	P,S,T	Domperidone	Oral liquid: 5mg /5ml , Tablet: 10 mg
123	T	Donepezil	Tablet:5mg

124	S,T	Dopamine	Injection: 40 mg (hydrochloride)in 5-ml vial
125	T	Doxorubicin	Powder for injection: 10 mg; 50 mg (hydrochloride) in vial
126	P,S,T	Doxycycline (ACCESS Group)	Capsule or Tablet:100 mg
	NP	Doxycycline (ACCESS Group)	Tablet: 100mg
127	P,S,T	Doxylamine + Pyridoxine	Tablet 10mg +10mg
128	T	Dydrogesterone	Tablets: 10 mg
129	NP	Efavirenz (EFV or EFZ)	Capsule: 50 mg, 100 mg,200 mg, Oral liquid: 150 mg/5 ml, Tablet: 600 mg
130	NP	Efavirenz + emtricitabine* + tenofovir	Tablet: 600 mg + 200 mg + 300 mg, * FTC is an acceptable alternative to 3TC; based on knowledge of the pharmacology; the resistance patterns and clinical trials of antiretrovirals
131	P,S,T	Elemental Zinc (sulphate )	Oral liquid: in 10 mg per unit dosage forms. *In acute diarrhoea zinc sulfate should be used as an adjunct to oral rehydration salts. Tablet: in 10 mg per unit dosage forms.
132	NP	Emtricitabine + Rilpivirine + Tenofovir	Tablets:600mg+300mg+200mg,200mg+300mg+600mg
133	NP	Emtricitabine* + tenofovir	Tablet: 200 mg + 300 mg * FTC is an acceptable alternative to 3TC; based on knowledge of the pharmacology; the resistance patterns and clinical trials of antiretrovirals
134	P,S,T	Enalapril	Tablet: 2.5 mg, 5mg; Injection 1.25mg/ml
135	Sp	Enoxaparin	injection: 40mg (equivalent to 4000 U), 60mg (equivalent to 6000 U) (sodium)
136	NP	Entecavir	Tablet 0.5mg, 1mg
137	S,T	Ephedrine	Injection:30 mg (hydrochloride)/ml in 1-ml ampoule
138	P,S,T	Epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule
139	S,T	Ergometrine	Injection: 200 micrograms (hydrogen maleate) in 1-ml ampoule
140	P,S,T	Erythromycin estolate (ACCESS Group)	Capsule or tablet: 250 mg (as stearate or ethyl succinate), Powder for injection: 500 mg (as lactobionate) in vial, Powder for oral suspension: 125 mg (as stearate or ethyl succinate)/5ml
141	T	<b>Erythropoietin</b>	Injection:2000IU/0.5ml
142	P,S,T	Escitalopram	Tablet:5mg,10mg,
143	T	Esmolol	Injection: 10mg /ml
144	S,T	Estrogen	Cream

145	NP	Ethambutol	Tablet: 100mg, 400 mg,600mg (hydrochloride)
146	P,S,T	Ethanol	Solution: 70% (denatured)
147	P,S,T	Ethinylestradiol	Tablet: 10 micrograms, 50 micrograms
148	Sp	Ethinylestradiol + cypoterone acetate	Tablet: 35 microgram + 2 mg (21 tablets packs)
149	P,S,T	Ethinylestradiol + levonorgestrel	Tablet: 30 micrograms + 150 micrograms
150	P,S,T	Ethinylestradiol + norethisterone	Tablet: 35 micrograms + 1.0 mg
151	NP	Ethionamide	Tablet: 125 mg; 250 mg
152	Sp	Etonogetrel (Implanon)	Implant: 68mg
153	Sp	Factor ix	Injection (dried)
154	Sp	Factor viii concentrate	Injection (dried)
155	S,T	Fentanyl	Injection: 50mcg mg/ml in 2-ml ampoule, Oral liquid: 2mg/5ml, Tablet: 2mg, 5mg
156	P,S,T	Ferrous salt	Oral solution: equivalent to 25 mg Elemental iron (as sulfate)/ml, Tablet: equivalent to 60 mg iron
157	P,S,T	Ferrous salt + folic acid	Tablet: equivalent to 60 mg iron + 400 micrograms folic acid
158	T	Filgrastim	Injection 300 mcg/0.5 ml
159	P,S,T	Finasteride	Tablet: 1mg, 5mg
160	T	Flucloxacillin (ACCESS Group)	Tablet/Capsule: 250mg, 500mg, Syrup: 125mg/5ml
161	P,S,T	Fluconazole	Injection:2 mg/ml in vial, Capsule or Tablet: 50mg,100mg,150 mg, Oral suspension: 50 mg/5-ml
162	P,S,T	Fluconazole	Eye drops: 0.3%
163	Sp	Fludrocortisone	Tablet: 0.1mg
164	S,T	Flumazenil	Injection: 100mcg/ml
165	S,T	Flunarizine	Tablets:5 mg,10 mg
166	T	Fluorouracil	Injection 50 mg/ mL in 5- mL ampoule
167	P,S,T	Fluoxetine	Capsules/tablet: 10mg, 20mg, Syrup: 20mg/5ml
168	P,S,T	Fluphenazine	Injection: 25 mg (decanoate or enantate) in 1-ml ampoule
169	T	Fluvoxamine	Tablet:50mg , 25mg ,100mg
170	P,S,T	Folic acid	Tablet: 1mg, 5mg
171	Sp	Folinic acid/Leucovorin	Tablet: 5mg, 10mg
172	P,S,T	Formaldehyde	Solution
173	Sp	Fresh Frozen Plasma(FFP)	Injection

174	P,S,T	Eurosemide	Injection: 10mg/ml in 2 ml ampoules/vials , Tablet: 20mg, 40mg
175	P,S,T	Fusidic Acid	Ointment , Cream
176	Sp	Gadolinium containing contrast for MRI	Injection:287mg/ml
177	Sp	Gastrografin (Sodium amidotrizoate + Meglumine amidotrizoate)	Oral solution: 660mg in 1 ml, 100mg in 1 ml, Rectal solution:
178	T	Gemcitabine	Powder for injection: 200 mg in vial, 1 g in vial
179	P,S,T	Gentamicin (ACCESS Group)	Injection:10 mg, 40 mg (as sulfate)/ml in 2-ml vial; Solution(eye drops): 0.3% (sulfate)
180	P,S,T	Glimepiride	Tablet: 1mg, 2mg , 3mg, 4mg
181	S,T	Glucagon	Injection 1mg/ml
182	P,S,T	Glucose	Injectable solution: 5%, 10% isotonic, 25% ,50% hypertonic
	S,T	Glucose with sodium chloride	Injectable solution: 4% glucose, 0.18% sodium chloride (equivalent to Na+ 30 mmol/l; Cl- 30 mmol/l)
183	P,S,T	Glucose with sodium chloride	Injectable solution: 5% glucose; 0.45% sodium chloride (equivalent to Na+ 154 mmol/l; Cl- 154 mmol/l), 4% glucose, 0.18% sodium chloride (equivalent to Na+ 30 mmol/l; Cl- 30 mmol/l)
184	P,S,T	Glycerin	Suppository: paediatric , adult
185	P,S,T	Glyceryl trinitrate	Injection: 5 mg/ml, Tablet(sublingual): 500 micrograms
186	P,S,T	Griseofulvin	Capsule or tablet: 125 mg, 250 mg
187	S,T	Haemodialysis concentrate	Parenteral solution
188	S,T	Haloperidol	Injection: 5 mg in 1-ml ampoule, 50mg /ml depo, Tablet: 2 mg, 5 mg
189	S,T	Halothane	Inhalation
190	Sp	Heparin sodium	Injection: 1000 IU/ml, 5000 IU/ml,20000 IU/ml in 1-ml ampoule
191	Sp	Hepatitis A vaccine	
192	S,T	Hepatitis B immunoglobulin (HBIG)	Injection 200U/ml
193	NP	Hepatitis B vaccine	
194	NP, SP	HiB Vaccine	
195	S,T	Human Chorionic Gonadotropin(HCG)	Injection: 5000IU, 10000IU
196	Sp	Human Milk fortifier	Sachets

197	Sp	Human normal immunoglobulin	Human normal immunoglobulin (intramuscular) administration: 16% protein solution. Intravenous administration: 5%; 10% protein solution.20%
198	Sp	Human Papilloma virus(HPV)	Bivalent+ quadrivalent
199	S,T	Hydralazine*	Injection: 20 mg/ml (hydrochloride) in ampoule *For use in the acute management of severe pregnancy-induced hypertension only Tablet: 25 mg,50 mg
200	P,S,T	Hydrochlorothiazide	Tablet (scored): 12.5mg, 25 mg, 50 mg
	P,S,T	Hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial
201	Sp	Hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial
	P,S,T	Hydrocortisone	Ointment or cream: 0.5%,1% (acetate)
	P,S,T	Hydrocortisone	Powder for injection: 100 mg/ml(as sodium succinate) in vial
202	P,S,T	Hydrogen Peroxide	Solution: 6%
203	T	Hydroxy propyl methyl cellulose	Solution:2%
204	T	Hydroxychloroquine phosphate	Tablet: 200 mg
205	P,S,T	Hyoscine butyl bromide	Injection: 20 mg/ml, Tablet: 10mg
206	P,S,T	Hypromellose	Gel
	Sp	Ibuprofen	Injection 5mg/ml
207	P,S,T	Ibuprofen	Oral liquid: 100mg/5ml, 200 mg, 400 mg Tablet:
208	T	Imatinib	Tablet: 100mg, 400mg
209	P,S,T	Imipramine	Tablets:25mg
210	Sp	Influenza vaccine (inactivated)	
211	S,T	Insulin glargine	injection
212	P,S,T	Insulin injection (soluble )	Injection: 40 IU/ml in 10-ml vial, 100 IU/ml in 10-ml vial
213	P,S,T	Intermediate-acting insulin (human)	Injection: 40 IU/ml in 10 ml vial, 100 IU/ml in 10 ml vial (as compound insulin zinc suspension or isophane insulin)
214	Sp	Intra lipid	Solution: 20% (TPN)
215	Sp	Iohexol	Injection: 140 –350 mg iodine/ml in 5-ml, 10-ml and 20-ml ampoule
216	P,S,T	Ipratropium bromide	Inhalation (aerosol): 20 micrograms/metered dose,
217	T	Iron+ dextran	Injection :50mg iron /ml

218	S,T	Isoflurane	Inhalation
219	NP	Isoniazid	Tablet: 100mg,300mg , Tablet (scored): 50 mg
220	S,T	Isoprenaline	Injection: 2mg (hydrochloride)/ml in ampoule
221	P,S,T	Isosorbide dinitrate	Tablet: 5 mg,10mg
222	S,T	Isoxsuprine	Tablet: 10mg,10mg retard, Injection: 10mg/ml
223	P,S,T	Itraconazole	Tablet: 100mg, 200mg
224	T	IV immunoglobulin (IVIG)	Injection 2.5g/vial, 5g/vial, 10g/vial
225	NP	Kanamycin	Powder for injection: 1000 mg in vial
226	S,T	Ketamine	Injection:50 mg (as hydrochloride)/ml in 10-ml vial,10mg/ml
227	P,S,T	Ketoconazole	Cream
228	S,T	Labetolol	Tablet: 100mg,200mg,300mg.Injection: 5mg/ml
229	P,S,T	Lactulose	Oral suspension: 667mg/ml
230	NP	Lamivudine (3TC)	Oral liquid: 50mg/5ml, Tablet:150mg
231	S,T	Lamotrigine	Tablet:25mg, 100mg
232	NP	Ledipasvir +Sofosbuvir	Tablet: 90mg + 400mg
233	Sp	Levodopa + Carbidopa	Tablet:100 mg + 10 mg
234	S,T	Levonorgestrel	Tablet: 0.75mg
235	Sp	Levonorgestrel (Mirena)	IUD
236	P,S,T	Levothyroxine	Tablet: 25 micrograms,50 micrograms,75 microgram,100 micrograms (sodium salt)
237	S,T	Lidocaine	Injection: 20 mg (hydrochloride)/ml in 5-ml ampoule; Injection for Spinal anaesthesia:5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution
	Sp	Lidocaine	Sprays: 4%
	P,S,T	Lidocaine	Injection: 1%-2% (hydrochloride) in vial, Topical forms: 2-5% (hydrochloride), 10% topical spray; 4% topical solution
238	S,T	Lidocaine + epinephrine (adrenaline)	Injection 1%, 2% (hydrochloride)+ epinephrine 1:200 000 in vial, Dental cartridge 2% (hydrochloride) + epinephrine 1:80 000
239	S,T	Lidocaine + Prilocaine	Cream: 5%
240	T	Lithium	Tablet: 300mg,450 mg
241	NP	Lopinavir + ritonavir (LPV/r)	Capsule: 133.3 mg + 33.3 mg, Oral liquid: 400 mg + 100 mg/5 ml
242	P,S,T	Loratadine	Tablet 10 mg

243	P,S,T	Lorazepam	Tablet: 1mg, 2mg, Injection: 2 mg/ml in 1-ml ampoule
244	P,S,T	Losartan potassium	Tablet: 25 mg, 50mg
245	S,T	Lynestrenol	Tablet:0.5mg
246	Sp	Magnesium sulfate	Injection:500 mg/ml in 2-ml ampoule,
247	P,S,T	Mannitol	Injectable solution:10%, 20%
248	NP	Measles + Rubella	
249	NP	Measles vaccine	
250	NP	Measles, mumps, rubella vaccine	
251	P,S,T	Mebendazole	Tablet: 100mg, Syrup:100mg/5ml
252	S,T	Medical Air	Inhalation (medicinal gas)
253	S,T	Medroxyprogesterone acetate	Depot injection: 150 mg/ml in 1-ml vial
254	T	Medroypregesterone	Tablets: 2.5 mg; 10 mg
255	P,S,T	Mefenamic Acid	Tablet: 250mg, 500mg
256	NP	Mefloquine	Tablet: 250 mg
257	Sp	Meningococcal meningitis vaccine	
258	S,T	Meropenem (WATCHED Group)	Powder for injection: 500 mg (as trihydrate); 1g (as trihydrate) in vial
259	P,S,T	Metformin	Tablet: 500 mg, 850mg, 1000mg SR (hydrochloride)
260	NP	Methadone	Concentrate for oral liquid:5mg/ml; 10mg/ml (hydrochloride) oral liquid:5mg/5ml;10mg/5ml (used under restricted program only)
261	S,T	Methotrexate	Tablet: 2.5mg, 5mg, 7.5mg, 10 mg, Injection:25mg/ml
	T	Methotrexate	Powder for injection: 50 mg (as sodium salt) in vial, Tablet: 2.5 mg (as sodium salt)
262	S,T	Methyldopa*	Tablet: 250 mg, 500mg *For use in the management of pregnancy-induced hypertension only.
263	Sp	Methylene blue	Aqueous solution
264	S,T	Methylprednisolone	Injection: 20mg/ml,40mg/ml,80mg/ml, Tablet: 2mg, 4mg
265	P,S,T	Metoclopramide	Injection: 5 mg (hydrochloride)/ml in 2-ml ampoule , Tablet: 10 mg (hydrochloride) Syrup: 5mg/5ml
266	P,S,T	Metolazone	Tablet: 2.5mg, 5mg,10mg
267	P,S,T	Metoprolol	Tablet: 25mg, 50 mg, Injection :5mg

268	P,S,T	Metronidazole (ACCESS Group)	Injection: 500 mg in 100-ml vial , Oral suspension: 100 mg (as benzoate)/5 ml, Tablet:200-500 mg, Gel: 0.75%
269	T	Micronised progesterone	Oral Tablet: 25 mg, 75 mg, 100mg, 200mg
270	P,S,T	Midazolam	Injection:1mg/ml ,5mg/ml in 2ml ampoule (hydrochloride), Tablet: 7.5mg , Syrup: 2mg/ml
271	S,T	Mifepristone	Tablet: 200 mg
272	S,T	Mirtazapine	Tablet :15mg
273	S,T	Misoprostol	Tablet: 25mcg, 50mcg, 100 mcg, 200 mcg
274	Sp	Morphine	Oral liquid: 10 mg (hydrochloride or sulfate)/5 ml, Tablet: 10mg,30mg modified release (sulfate)
275	S,T	Morphine sulphate	Injection: 10mg/1ml ampoule (sulfate or hydrochloride); Oral liquid: 10mg/5ml (hydrochloride or sulfate); Tablet: 10mg, 15mg, 30mg modified release (sulfate)
276	P,S,T	Mupirocin	Ointment, Cream
277	S,T	N-acetyl Cysteine	Injection: 200 mg/ml, Tablet: 600mg
278	S,T	Naloxone	Injection: 400 micrograms (hydrochloride) in 1-ml ampoule
279	T	Naltrexone	Tablet:50mg
280	P,S,T	Natamycin	Eye drops: 0.3%
281	NP	Nelfinavir (NFV)	Oral powder: 50 mg/g, Tablet or Tablet: 250 mg (as mesilate)
282	S,T	Neostigmine	Injection: 500 mcg in 1-ml ampoule, 250 mcg (metilsulfate) in 1-ml ampoule, Tablet: 15 mg (bromide)
283	S,T	Nepafenac	Eye drop
284	NP	Nevirapine (NVP)	Oral liquid: 50 mg/5 ml, Tablet: 200 mg
285	P,S,T	Nicotine replacement therapy (NRT)	Chewing gum: 2 mg; 4 mg (as polacrilex). Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs.
286	S,T	Nifedipine	Capsule/Tablet:10mg , retard 10mg, 20mg
287	S,T	Nitrofurantoin (ACCESS Group)	Tablet/Capsule: 100mg
288	S,T	Nitroglycerine	Ointment: 0.2%
289	S,T	Nitrous oxide	Inhalation
290	P,S,T	Normal saline	0.9% solution for nasal use

291	S,T	Nystatin	Lozenge: 100 000 IU; Pessary: 100 000 IU; Tablet: 100 000, 500 000 IU; Oral Drops: 100 000 IU
292	T	Octreotide	Injection:50mg, 100mg
293	NP	Ofloxacin	Tablet: 100mg,200 mg,400 mg
294	S,T	Ofloxacin + dexamethasone	Solution eye/ear drops
295	S,T	Olanzapine	Tablet: 2.5mg, 5mg
296	P,S,T	Olopatadine	Eye solution: 0.1%
297	S,T	Ondansetron	Injection: 2mg/ml in 2-ml ampoule, 4mg, 8mg in 2-ml ampoule, Tablet: 4mg, 8mg, Syrup: 2mg/5ml
298	P,S,T	Oral rehydration salts * (for glucose-electrolyte solution)	glucose: 75 mEq, sodium: 75 mEq or mmol/l, chloride: 65 mEq or mmol/l, potassium: 20 mEq or mmol/l , citrate: 10 mmol/l, osmolarity: 245 mOsm/l, glucose: 13.5 g/l, sodium chloride: 2.6 g/l, potassium chloride: 1.5 g/l, trisodium citrate dihydrate: 2.9 g/l, * in cases of cholera a higher concentration of sodium may be required
299	T	Oseltamivir	Capsule: 30mg, 45mg, 75 mg, Oral Syrup: 12mg/ml
300	T	Oxaliplatin	Injection: 50 mg/10 mL in 10- mL vial; 100 mg/20 mL in 20- mL vial
301	Sp	Oxybutynin	Tablet: 2.5mg, 5mg
302	P,S,T	Oxygen	Inhalation (medicinal gas)
303	P,S,T	Oxymetazoline	Solution (nose drops): 0.05%. 0.025%
304	P,S,T	Oxytocin	Injection:5IU/ml ,10 IU in 1-ml ampoule
305	T	Paclitaxel	Powder for injection: 6 mg/mL
306	P,S,T	Pantoprazole	Tablet: 40mg, 20mg; Injection: 40mg
307	P,S,T	Paracetamol	Oral liquid: 120mg/5ml, 125mg/5ml; 250mg/5ml; Tablet: 500 mg; Injection:1g/100ml; Suppository: 100 mg
308	P,S,T	Paracetamol	Oral liquid: 125 mg/5ml, 250mg/5ml, Tablet: 500 mg, Injection 1 g/100ml, Suppository: 100 mg, 125mg, 250mg, 500mg
309	P,S,T	Penicillin V (ACCESS Group)	Tablet: 250mg, 500mg, Syrup: 125mg/5ml
310	S,T	Peritoneal dialysis concentrate	Solution
311	S,T	Permethrin	Cream: 5% for (scabies),1% for lice treatment, Lotion: 5% for (scabies),1% for lice treatment
312	S,T	Pethidine	Injection: 50 mg/ml (hydrochloride)

313	S,T	PGE2 (Dinoprostone)	Injection: 0.5%
314	S,T	PGF2 alpha (Carboprost)	Injection: 250mcg
315	P,S,T	Pheniramine maleate	Injection 25mg/10ml
316	P,S,T	Phenobarbital	Oral liquid 20 mg/5ml, Tablet:30mg,60mg, Injection: 200 mg/ml
317	P,S,T	Phenylephrine	Solution (eye drops):0.12%
318	P,S,T	Phenytoin sodium	Injection: 50 mg/ml(sodium salt) in 5-ml vial, Capsule: 25 mg, 50 mg, 100 mg (sodium salt), Oral liquid:25mg to 30mg/5 ml,Tablet: 25 mg,50 mg, 100 mg (sodium salt)
319	P,S,T	Phytomenadione (vitamin k1)	Injection:10 mg/ml in 5-ml ampoule
320	S,T	Pilocarpine	Solution (eye drops); 2%; 4% (hydrochloride or nitrate)
	T	Pilocarpine nitrate	Injection:0.5%
321	T	Piperacillin +tazobactam (WATCHED Group)	Injection:2.25g, 4.5g
322	Sp	Platelet concentrate	
323	Sp	Pneumococcal conjugated vaccine	
324	Sp	Pneumococcal polysaccharide vaccine	
325	S,T	Podophyllum resin	Solution: 10, 25%
326	NP	Polio vaccine- Oral (b OPV)	
327	NP	Polio vaccine- Oral (m OPV)	
328	NP	Polio vaccine-Inactivated (IPV)	
329	S,T	Polymyxin (RESERVED group)	Powder for injection: 1 million I.U. (as colistemethate sodium) in vial
330	P,S,T	Potassium chloride	Injectable solution, Tablet: 600mg , Syrup
331	P,S,T	Potassium permanganate	Solution (aqueous): 1in10;000, crystals, powder
332	P,S,T	Povidone Iodine	Ointment and cream: 5%w/w; Solution: 5, 10%
333	S,T	Prazosin	Tablet:2mg
334	P,S,T	Prednisolone	Oral Tablet: 5mg, 10mg, 20mg, 40mg; Oral liquid: 3mg/5ml, 5mg/5ml; Solution (eye drops): 0.5% (sodium phosphate)
335	P,S,T	Premix insulin	Injection:30:70 40IU/ml
336	NP	Primaquine	Tablet:7.5 mg,15 mg

337	S,T	Procaine benzylpenicillin (ACCESS Group)	Injection 1.2 million IU
338	P,S,T	Prochlorperazine	Injection: 12.5mg/ml ampoule
339	NP	Proguanil	Tablet 100mg
340	P,S,T	Promethazine	Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule, Oral liquid: 5 mg (hydrochloride)/5 ml, Tablet: 10 mg, 25 mg (hydrochloride)
341	P,S,T	Propacaine	Eye drops: 0.5%
342	S,T	Propofol	Injection:10mg/ml, 20mg/ml
343	P,S,T	Propranolol	Tablets: 5 mg,10 mg,40 mg
344	S,T	Propylthiouracil	Tablet: 50 mg
345	Sp	Prostaglandins E	Solution for injection prostaglandin E1 0.5mg/ml in alcohol,; prostaglandin E2 1mg/ml
346	Sp	Protamine sulfate	Injection: 10 mg/ml in 5-ml ampoule
347	NP	Pyrazinamide	Tablet: 400 mg,500mg,750mg,1000mg
348	S,T	Pyridostigmine	Injection: 1 mg in 1-ml ampoule, Tablet: 60 mg (bromide)
349	NP	Pyridoxine	Tablet :50mg, 40mg
	P,S,T	Pyridoxine	Tablet:10mg, 40mg
350	Sp	Pyrimethamine	Tablet: 25mg
351	T	Quetiapine	Tablet: 25mg, 50mg, 100mg, 300mg
352	NP	Quinine	Tablet: 300mg, 100 mg, Syrup:150mg/ml, Injection:300 mg/ml 2ml, 80mg/ml
353	P,S,T	Ranitidine	Injection: 25 mg/ml in 2-ml ampoule, Oral liquid: 75 mg/5-ml, Tablet: 150 mg (as hydrochloride)
354	NP,T	Retinol	Sugar-coated tablet; 10 000 IU (as palmitate) (5.5 mg); capsule;200 000 IU (as palmitate) (110 mg); oral oily solution 100 000 IU (as palmitate)/ml in multidose dispenser; water-miscible injection 100 000 IU (as palmitate) (55 mg) in 2-ml ampoule
	NP	Ribavarin	Capsule: 200mg
355	T	Ribavarin	Tablet: 200, 400, 600mg , Oral solution: 40mg/ml
356	NP,T	Rifampicin	Capsule or Tablet: 150 mg, 300 mg; Syrup:200mg/5ml,100mg/5ml

357	NP	Rifampicin + isoniazid	Tablet:60 mg + 30 mg; 150 mg + 75 mg; 300 mg + 150 mg; 75mg + 50mg , 60 mg + 60 mg (for intermittent use three times weekly), 150 mg + 150 mg (for intermittent use three times weekly)
358	NP	Rifampicin + isoniazid + ethambutol	Tablet: 150 mg + 75 mg + 275 mg.
359	NP	Rifampicin + isoniazid + pyrazinamide + ethambutol	Tablet: 150 mg + 75 mg + 400 mg + 275 mg.
360	S,T	Risperidone	Tablet: 1mg, 2mg, Oral liquid: 1mg/ml Injection : Depo
361	NP	Ritonavir	Oral liquid: 400 mg/5 ml, Capsule or Tablet:100mg
362	T	Rituximab	Injection: 100 mg/10 mL in 10- mL vial
363	S,T	Rocuronium	Injection: 50mg/5ml
364	T	Ropinarole	Tablet:0.5mg, 1mg , 2mg
365	P,S,T	Salbutamol	Inhalation (aerosol):100 micrograms (as sulfate) per dose , Injection: 0.5mg(as sulfate)/ml, Respirator solution for use in nebulizers: 5 mg (as sulfate)/ml, Tablet: 2 mg, 4 mg (as sulfate)
366	S,T	Salicylic acid	Solution: 5%, Ointment 20%
367	T	Sildenafil	Tablet: 20mg , Syrup: 10mg/1ml
368	P,S,T	Silver sulfadiazine	Cream: 1%
369	P,S,T	Simethicone	Tablet: 80 mg, Drops: 20 mg, Syrup: 2% emulsion 120 ml
370	S,T	Sitagliptin	Tablet
371	P,S,T	Sodium Alginate + Magnesium Alginate	Syrup, Powder
372	P,S,T	Sodium chloride	Injectable solution: 0.9% isotonic (equivalent to Na+ 154 mmol/l; Cl- 154 mmol/l) , 3%
373	T	Sodium chloride (hypersol)	Solution: 5%
374	P,S,T	Sodium Citrate + Citric acid	Sachet, Syrup
375	P,S,T	Sodium hydrogen carbonate (Sodium bicarbonate)	Injectable solution: 1.4% isotonic (equivalent to Na+ 167 mmol/l; HCO3- 167 mmol/l); solution; 7.5% in 10-ml ampoule (equivalent to Na+ 1000 mmol/l; HCO3- 1000 mmol/l), sachetts, tablets
376	P,S,T	Sodium lactate; compound solution (Ringer Lactate)	Injectable solution
377	S,T	Sodium Nitrite	Injection :30mg/ml in 10ml ampoule
378	T	Sodium nitroprusside	Powder for infusion: 50 mg/5ml in ampoule

379	P,S,T	Sodium phosphate monohydrate +Sodium phosphate hepta hydrate	Disposable Enema
380	NP	Sofosbuvir	Tablet: 400mg
381	Sp	Spiramycin	Tablet: 1.5MIU, 3 MIU
382	P,S,T	Spironolactone	Tablet: 25 mg,50mg
383	S,T	Streptokinase	Powder for injection:1.5 million IU in vial
384	NP	Streptomycin	Powder for injection: 1 g (as sulfate) in vial
385	P,S,T	Sucralfate	Syrup: 1000mg/10ml
386	P,S,T	Sulfamethoxazole + trimethoprim (ACCESS Group)	Oral suspension: 200 mg + 40 mg/5 ml Tablet:100 mg + 20 mg, 400 mg + 80 mg
387	S,T	Sulfasalazine	Tablet: 500mg
388	Sp	Sulphadiazine	Tablets: 500mg
389	NP	Sulphadoxine + pyrimethamine	Tablet:500 mg + 25mg
390	T	Sumatriptan	Tablet :25mg, 50mg
391	Sp	Surfactants	Suspension for intra-tracheal instillation 25mg/ml and 80mg/ml
392	S,T	Suxamethonium	Injection: 50 mg (chloride)/ml in 2-ml ampoule
393	Sp	Tamoxifen	Tablet:10 mg, 20 mg (as citrate)
394	S,T	Tamsulosin	Capsule: 0.4mg
395	NP	Td	
396	P,S,T	Tears natural	Solution (eye drops): dextran 70.1% hypromellose 0.3%
397	NP	Tenofovir	Tablet: 300mg
398	NP	Tenofovir + Emtricitabine	Tablet 300mg+ 200 mg
399	NP	Tenofovir disoproxil fumarate (TDF)	Tablet: 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
400	T	Terlipressin	Injection: 1mg, 2mg
401	Sp	Testosterone	Capsule :40mg, Injection:100mg/ml, 200mg/ml
402	S,T	Tetracaine	Solution (eye drops): 0.5% (hydrochloride)
403	P,S,T	Theophylline	Tablet
404	S,T	Thiamine	Tablet: 75mg.; Injection 100mg
405	S,T	Timolol	Solution (eye drops): 0.25%, 0.5% (as maleate)
406	P,S,T	Tinidazole	Tablet: 500mg, 1gm, 2gm
407	P,S,T	Tobramycin	Eye drops, eye ointment
408	S,T	Tobramycin + dexamethasone	Eye drops
409	P,S,T	Topiramate	Tablet: 25mg and 50mg

410	P,S,T	Torsemide	Tablet: 5mg , 10mg, 20mg, 100mg. Injection: 10mg/ml
411	S,T	Tramadol	Injection: 50 mg/ml in 2ml ampoule, Capsules: 50mg, Tablets: 50mg
412	T	Tranexamic acid	Tablet: 500mg,100mg, Injection: 100mg/ml
413	T	Trastuzumab	Powder for injection: 60 mg; 150 mg; 440 mg in vial
414	P,S,T	Tretinoin	Cream: 0.025%
415	P,S,T	Triamcinolone	Injection: 10mg, 40mg (acetonide), Oral gel
416	Sp	Trihexyphenidyl HCL	Tablet: 2 mg
417	P,S,T	Tropicamide	Eye drops: 0.5%, 1%
418	T	Trypan Blue	Solution:0.06%
419	S,T	Tuberculin: purified protein derivative (PPD)	Injection: 5 TU , 10 TU
420	Sp	Typhoid vaccine	
421	S,T	Urea	Ointment and cream: 10%
422	P,S,T	Ursodeoxycholic Acid	Tablet: 150 mg, 300 mg
423	S,T	Valethamate	Injection: 8mg
424	P,S,T	Valproic acid	Oral liquid: 200mg/5ml, Tablet (enteric coated) : 200 mg, 500 mg (sodium salt)
	S,T	Valproic acid	Injection: 100mg/ml
425	T	Vancomycin hydrochloride (RESERVED group)	Powder for injection: 250 mg,500mg (as hydrochloride) in vial
426	S,T	Varicella immunoglobulin (VZIG)	Injection 125 IU
427	Sp	Varicella vaccine	
428	T	Venlafaxine	Tablet :25mg, 37.5mg,75mg
429	S,T	Verapamil	Injection: 2.5 mg (hydrochloride)/ml in 2-ml ampoule (hydrochloride), Tablet: 40mg, 80mg
	P,S,T	Verapamil	Tablet: 40 mg, 80 mg (hydrochloride)
430	T	Vincristine	Powder for injection: 1 mg; 5 mg (sulfate) in vial.
431	P,S,T	Vitamin B complex	Capsule: Vit B 1 mg, Vit B2 1 mg ; Tablet: Vit B 1 mg, Vit B2 1 mg
432	Sp	Warfarin	Tablet: 1 mg; 2 mg and 5 mg (sodium salt)
433	P,S,T	Water for injection	2-ml; 5-ml; 10-ml ampoules
434	S,T	White paraffin	Cream, liquid
435	Sp	Yellow fever vaccine	
436	NP	Zidovudine (ZDV or AZT)	Capsule: 100 mg, 250 mg., Oral liquid: 50 mg/5 ml., Solution for IV infusion injection: 10 mg/ml in 20-ml vial., Tablet: 100mg,300 mg.

437	NP	Zidovudine + lamivudine	Tablet: 300 mg + 150 mg
438	NP	Zidovudine + lamivudine + nevirapine	Tablet: 300 mg + 150 mg + 200mg
439	P,S,T	Zinc oxide	Paste, Cream, Powder
440	S,T	Zoledronate	Injection: 4mg

## XI. Essential Medicine List 2018 (with Classifications)

<b>1. ANAESTHETICS</b>				
<b>1.1 General anaesthetics and oxygen medical gas</b>				
No	Level	Medicine	Dosage Form and Strength	Notes
1.	S,T	Halothane	Inhalation	
2.	S,T	Isoflurane	Inhalation	Alternative Sevoflurane Inhalation
3.	S,T	Ketamine	Injection:50 mg (as hydrochloride)/ml in 10-ml vial,10mg/ml	
4.	S,T	Nitrous oxide	Inhalation	
5.	P,S,T	Oxygen	Inhalation (medicinal gas)	
6.	S,T	Propofol	Injection:10mg/ml, 20mg/ml	Alternative Thiopentone (thiopental) Powder for injection: 0.5 g, 1.0 g (sodium salt) in ampoule
7.	S,T	Medical Air	Inhalation (medicinal gas)	
8.	T	Chloral Hydrate	Syrup: 250mg/5ml	
<b>1.2 Local anaesthetics</b>				
	Level	Medicine	Dosage Form and Strength	Notes
9.	S,T	Lidocaine	Injection for Spinal anaesthesia:5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution	
10.	P,S,T	Lidocaine	Injection: 1%-2% (hydrochloride) in vial Topical forms: 2-5% (hydrochloride), 10% topical spray	
11.	S,T	Lidocaine + epinephrine (adrenaline)	Injection 1%, 2% (hydrochloride)+ epinephrine	

			1:200 000 in vial Dental cartridge 2% (hydrochloride) + epinephrine 1:80 000	
12.	S,T	Bupivacaine	Injection for Spinal anesthesia : 0.5% (hydrochloride) in 4-ml ampoule with 7.5% glucose solution	
			Injection: 0.25%,0.5% (hydrochloride) in vial	
13.	S,T	Ephedrine	Injection:30 mg (hydrochloride)/ml in 1-ml ampoule	For use in spinal anesthesia during delivery to prevent hypotension
14.	S,T	Lidocaine + Prilocaine	Cream: 5%	

**1.3 Preoperative medication and sedation for short-term procedures**

	Level	Medicine	Dosage Form and Strength	Notes
15.	P,S,T	Atropine sulphate	Injection: 0.6 mg in 1-ml ampoule	
16.	S,T	Fentanyl	Injection: 50mcg mg/ml in 2-ml ampoule	
			Oral liquid: 2mg/5ml	
			Tablet: 2mg, 5mg	
17.	S,T	Morphine sulphate	Tablet: 10mg ,15mg, 30 mg ,	
			Syrup: 10mg/5ml	
			Injection: 10 mg (sulfate or hydrochloride) in 1-ml ampoule	
18.	P,S,T	Midazolam	Injection: 5mg/ml in 2ml ampoule (hydrochloride)	
19.	T	Esmolol	Injection: 10mg /ml	For preoperative hypertension & tachycardia

**2. ANALGESICS,ANTIPYRETICS, NON-STEROIDAL ANTI-INFLAMMATORY MEDICINES (NSAIMs), GOUT AND RHEUMATOID DISORDER AGENTS (DMARDs)****2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)**

	Level	Medicine	Dosage Form and Strength	Notes
20.	P,S,T	Ibuprofen	Oral liquid: 100mg/5ml Tablet: 200 mg, 400 mg	
21.	P,S,T	Paracetamol	Oral liquid: 125 mg/5ml, 250mg/5ml	
			Tablet: 500 mg	
			Injection 1 g/100ml	
			Suppository: 100 mg	
22.	P,S,T	Diclofenac sodium	Injection: 25 mg/ml in 3-ml ampoule	
			Tablet: 25mg,50mg enteric	

			coated Suppository:12.5mg, 50mg	
23.	P,S,T	Mefenamic Acid	Tablet: 250mg, 500mg	

**2.2 Opioid analgesics**

	Level	Medicine	Dosage Form and Strength	Notes
24.	S,T	Morphine sulphate	Injection:10 mg(sulfate or hydrochloride) in 1-ml ampoule	
			Oral liquid: 10 mg (hydrochloride or sulfate)/5 ml	
			Tablet: 10mg, 30mg modified release (sulfate)	
25.	S,T	Tramadol	Injection: 50 mg/ml in 2ml ampoule	
			Capsules: 50mg	
			Tablets: 50mg	
26.	S,T	Pethidine	Injection: 50 mg/ml (hydrochloride)	Repeated administration of pethidine causes addictive effect

**2.3 Medicines used to treat gout**

	Level	Medicine	Dosage Form and Strength	Notes
27.	S,T	Allopurinol	Tablet:100 mg	

**2.4 Disease modifying agents used in rheumatoid disorders (DMARDs)**

	Level	Medicine	Dosage Form and Strength	Notes
28.	S,T	Methotrexate	Tablet: 2.5mg, 5mg, 7.5mg, 10 mg	
			Injection:25mg/ml	
29.	T	Hydroxychloroquine phosphate	Tablet: 200 mg	
30.	S,T	Sulfasalazine	Tablet: 500mg	

**3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS**

	Level	Medicine	Dosage Form and Strength	Notes
31.	P,S,T	Cetirizine	Oral liquid: 5mg/ml	
			Tablets: 10 mg	
32.	P,S,T	Chlorpheniramine maleate	Injection: 10 mg (hydrogen maleate) in 1-ml ampoule	
			Oral liquid: 2 mg/5 ml	
			Tablet: 4 mg (hydrogen maleate)	
33.	P,S,T	Dexamethasone	Injection: 4 mg dexamethasone phosphate (as disodium salt) in 1-ml ampoule	
34.	P,S,T	Hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial	
35.	P,S,T	Prednisolone	Oral Tablet: 5 mg,10mg,20mg ,40mg	

36.	P,S,T	Adrenaline	Injection:1mg/ml (1 in 1000) , 0.5mg/ml ( 1 in 10,000)	
37.	P,S,T	Pheniramine maleate	Injection 25mg/10ml	
38.	P,S,T	Loratadine	Tablet 10 mg	Non sedative anti histamine

**4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING****4.1 Non Specific**

	Level	Medicine	Dosage Form and Strength	Notes
39.	P,S,T	Charcoal activated	Powder, 50g cans or packs	

**4.2 Specific**

	Level	Medicine	Dosage Form and Strength	Notes
40.	S,T	N-acetyl Cysteine	Injection: 200 mg/ml Tablet: 600mg	
41.	S,T	Atropine sulphate	Injection: 0.6 mg,1mg (sulfate) in 1-ml ampoule	
42.	P,S,T	Desferrioxamine	Injection: 500 mg/ml (mesylate) in ampoule	For thalassemia patients
43.	S,T	Flumazenil	Injection: 100mcg/ml	
44.	S,T	Naloxone	Injection: 400 micrograms (hydrochloride) in 1-ml ampoule	
45.	S,T	Sodium Nitrite	Injection :30mg/ml in 10ml ampoule	
46.	P,S,T	Deferiprone	Tablet:500mg	For thalassemia children with liver disease
47.	P,S,T	Deferasirox	Tablet:125mg, 250mg , 500mg	For thalassemia with neutropenia
48.	T	Dantrolene Sodium	Injection: 20mg	Malignant hyperthermia

**5. ANTICONVULSANTS/ANTIEPILEPTICS**

	Level	Medicine	Dosage Form and Strength	Notes
49.	P,S,T	Carbamazepine	Oral liquid: 100mg/5ml Tablet (scored): 100 mg, 200 mg	
50.	P,S,T	Diazepam	Injection: 5 mg/ml in 2-ml ampoule intravenous. Rectal solution and suppository Tablet: 2mg, 5mg,10mg Syrup: 2mg/5ml	
51.	P,S,T	Lorazepam	Tablet: 1mg, 2mg Injection: 2 mg/ml in 1-ml ampoule	
52.	Sp	Magnesium sulfate	Injection:500 mg/ml in 2-ml ampoule, 250mg/ml in 5-ml ampoule	For use in eclampsia and severe pre-

				eclampsia and not for other convulsant disorders.
53.	P,S,T	Phenobarbital	Oral liquid 20 mg/5ml Tablet:30mg,60mg Injection: 200 mg/ml	
54.	P,S,T	Phenytoin sodium	Injection: 50 mg/ml(sodium salt) in 5-ml vial  Capsule: 25 mg, 50 mg, 100 mg (sodium salt) Oral liquid:25mg to 30mg/5 ml Tablet: 25 mg,50 mg, 100 mg (sodium salt)	It may cause cardiac arrhythmia if infused too quickly
55.	P,S,T	Valproic acid	Oral liquid: 200mg/5ml Tablet (enteric coated) : 200 mg,500 mg (sodium salt)	
56.	S,T	Valproic acid	Injection: 100mg/ml	

## 6. ANTI-INFECTIVE MEDICINES

### 6.1 Anthelmintics

#### 6.1.1 Intestinal anthelmintics

	Level	Medicine	Dosage Form and Strength	Notes
57.	P,S,T	Albendazole	Oral liquid: 200mg/5ml Tablet: 200mg, 400 mg	
58.	P,S,T	Mebendazole	Tablet: 100mg Syrup:100mg/5ml	

#### 6.1.2 Antifilarials

	Level	Medicine	Dosage Form and Strength	Notes
59.	NP	Diethylcarbamazine	Tablet: 50 mg,100 mg	

### 6.2. Antibacterials

#### 6.2.1 Beta Lactam medicines

	Level	Medicine	Dosage Form and Strength	Notes
60.	P,S,T	Amoxicillin <b>(ACCESS Group)</b>	Capsule or Tablet; 250 mg, 500 mg (anhydrous) .  Powder for oral suspension: 125 mg (anhydrous)/5 ml	
61.	P,S,T	Amoxicillin + clavulanic acid <b>(ACCESS Group)</b>	Oral liquid: 156.25mg/5ml (125mg+31.25mg/5l), 312.5mg/5ml (250mg+62.5mg/5ml), 228.5mg/5ml	

			(200mg +28.5mg/5ml) , 278.5mg/5ml (250mg+28.5mg/5ml)	
			Tablet: 625 mg, 375mg	
			Oral drops 62.5mg/ml	
			Powder for injection: 600 mg, 1.2 g in vial	
62.	P,S,T	Ampicillin <b>(ACCESS Group)</b>	Powder for injection: 500 mg, 1 g (as sodium salt) in vial	
			Tablet: 500 mg	
63.	P,S,T	Benzathine benzylpenicillin <b>(ACCESS Group)</b>	powder for injection: 1.44 g benzylpenicillin (=2.4 million IU), in 5-ml vial, 1.2million IU	
64.	S,T	Procaine benzylpenicillin <b>(ACCESS Group)</b>	Injection 1.2 million IU	
65.	S,T	Meropenem <b>(WATCHED Group)</b>	Powder for injection: 500 mg (as trihydrate); 1 g (as trihydrate) in vial	
66.	P,S,T	Benzylpenicillin <b>(ACCESS Group)</b>	Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium salt) in vial	
67.	S,T	Cefuroxime <b>(WATCHED Group)</b>	Injections: 250 mg, 500 mg	
			Tablets: 125 mg, 250 mg (as cefuroxime axetil)	
68.	S,T	Ceftazidime <b>(WATCHED Group)</b>	Powder for injection: 250 mg (as pentahydrate) in vial	
69.	S,T	Cefotaxime <b>(WATCHED Group)</b>	Injection: 250mg, 500 mg, 1g	
70.	S,T	Ceftriaxone <b>(WATCHED Group)</b>	Injection: 250mg, 1 g	
71.	P,S,T	Cefixime <b>(WATCHED Group)</b>	Tablet 100mgDT, 200mg,400mg	
			Syrup 50mg/5ml	
72.	T	Piperacillin +tazobactam <b>(WATCHED Group)</b>	Injection:2.25g, 4.5g	
73.	T	Cefazolin	Injection: 500mg, 1gm	
74.	T	Cefadroxil	Tablet: 250mg, 500mg	
			Syrup: 125mg/5ml	
75.	T	Flucloxacillin <b>(ACCESS Group)</b>	Tablet/Capsule: 250mg, 500mg	
			Syrup: 125mg/5ml	
76.	P,S,T	Penicillin V <b>(ACCESS Group)</b>	Tablet: 250mg, 500mg	
			Syrup: 125mg/5ml	

#### 6.2.2 Other antibacterials

	Level	Medicine	Dosage Form and Strength	Notes
77.	S,T	Azithromycin	Tablet: 250 mg, 500mg,	

		<b>(WATCHED Group)</b>	1000mg Oral liquid: 100g/5ml (for restricted indications only), Injection: 500 mg	
78.	P,S,T	Ciprofloxacin <b>WATCHED Group.</b>	Tablet: 250 mg,500mg (as hydrochloride)	
79.	S,T	Clarithromycin <b>(WATCHED Group)</b>	Tablets: 250mg; 500 mg (for restricted indications only)	
80.	P,S,T	Doxycycline <b>(ACCESS Group)</b>	Capsule or Tablet:100 mg (hydrochloride)	
81.	P,S,T	Erythromycin estolate <b>(ACCESS Group)</b>	Capsule or tablet: 250 mg (as stearate or ethyl succinate )	
			Powder for injection: 500 mg (as lactobionate) in vial	
			Powder for oral suspension: 125 mg (as stearate or ethyl succinate)/5ml	
82.	P,S,T	Gentamicin <b>(ACCESS Group)</b>	Injection:10 mg, 40 mg (as sulfate)/ml in 2-ml vial	
83.	S,T	Amikacin sulphate <b>(ACCESS Group)</b>	Injection: 250 mg in 2ml aqueous solution in vial for paediatric use	
84.	P,S,T	Metronidazole <b>(ACCESS Group)</b>	Injection: 500 mg in 100-ml vial	
			Oral suspension: 100 mg (as benzoate)/5 ml	
			Tablet:200-500 mg	
			Gel: 0.75%	
85.	P,S,T	Sulfamethoxazole + trimethoprim <b>(ACCESS Group)</b>	Oral suspension: 200 mg + 40 mg/5 ml	
			Tablet:100 mg + 20 mg, 400 mg + 80 mg	
86.	T	Vancomycin hydrochloride <b>(RESERVED group)</b>	Powder for injection: 250 mg,500mg (as hydrochloride) in vial	
87.	S,T	Polymyxin <b>(RESERVED group)</b>	Powder for injection: 1 million I.U. (as colistemethate sodium) in vial	
88.	S,T	Chloramphenicol <b>(ACCESS Group)</b>	Capsules: 250mg	
			Oral suspension: 150mg (as palmitate) /5ml	
			Powder for injection 1g (sodium succinate)/ml in 2-ml I ampoule.	
89.	P,S,T	Tinidazole	Tablet: 500mg, 1gm, 2gm	
90.	S,T	Nitrofurantoin <b>(ACCESS Group)</b>	Tablet/Capsule: 100mg	

91.	S,T	Colistin <b>(RESERVED group)</b>	Injection: 150mg/vial	
-----	-----	-------------------------------------	-----------------------	--

**6.2.3 Antileprosy medicines**

Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance.

	Level	Medicine	Dosage Form and Strength	Notes
92.	NP	Clofazimine	Capsule: 50 mg, 100 mg	
93.	NP,T	Dapsone	Tablet: 25 mg, 50 mg, 100 mg	
94.	NP,T	Rifampicin	Capsule or tablet: 150 mg, 300 mg	

**6.2.4 Antituberculosis medicine**

	Level	Medicine	Dosage Form and Strength	Notes
95.	NP	Ethambutol	Tablet: 100mg, 400 mg,600mg (hydrochloride)	
96.	NP	Isoniazid	Tablet: 100mg,300mg , Tablet (scored): 50 mg	
97.	NP	Pyrazinamide	Tablet: 400 mg,500mg,750mg,1000mg	
98.	NP	Rifampicin	Capsule or Tablet: 150 mg, 300 mg, Syrup: 200mg/5ml,100mg/5ml	
99.	NP	Rifampicin + isoniazid	Tablet:60 mg + 30 mg; 150 mg + 75 mg; 300 mg + 150 mg; 75mg + 50mg 60 mg + 60 mg (for intermittent use three times weekly) 150 mg + 150 mg (for intermittent use three times weekly)	
100.	NP	Rifampicin + isoniazid + ethambutol	Tablet: 150 mg + 75 mg + 275 mg.	
101.	NP	Rifampicin + isoniazid + pyrazinamide + ethambutol	Tablet: 150 mg + 75 mg + 400 mg + 275 mg.	
102.	NP	Streptomycin	Powder for injection: 1 g (as sulfate) in vial	
103.	NP	Pyridoxine	Tablet :50mg, 40mg	

**6.2.5 Reserve second - line drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used adhering to WHO Standards for TB control**

	Level	Medicine	Dosage Form and Strength	Notes
104.	NP	Amikacin	Powder for injection: 1000 mg in	

			vial	
105.	NP	Cycloserine	Capsule or tablet: 250 mg	
106.	NP	Ethionamide	Tablet: 125 mg; 250 mg	
107.	NP	Kanamycin	Powder for injection: 1000 mg in vial	
108.	NP	Oflloxacin	Tablet: 100mg,200 mg,400 mg	Levofloxacin as alternative based on availability

**6.3 Antifungal medicines**

	Level	Medicine	Dosage Form and Strength	Notes
109.	P,S,T	Fluconazole	Injection:2 mg/ml in vial	
			Capsule or Tablet: 50mg,100mg,150 mg	
			Oral suspension: 50 mg/5-ml	
110.	P,S,T	Griseofulvin	Capsule or tablet: 125 mg, 250 mg	
111.	S,T	Nystatin	Lozenge: 100 000 IU	
			Pessary: 100 000 IU	
			Tablet:100 000, 500 000 IU	
			Oral Drops 100 000 IU	
112.	P,S,T	Itraconazole	Tablet: 100mg, 200mg	
113.	S,T	Amphotericin B	Injection:50mg/vial ( conventional or liposomal complex)	
114.	P,S,T	Clotrimazole	Vaginal Tablets: 100mg, 200mg Gel : 1%, 10 %	

**6.4 Antiviral medicines****6.4.1 Antiherpes medicines**

	Level	Medicine	Dosage Form and Strength	Notes
115.	S,T	Acyclovir	Cream: 3% ,5%	
			Injection:250 mg (as sodium salt) in vial	
			Tablet: 200 mg, 400mg , 800 mg	
			Syrup: 200mg/5ml	

**6.4.2 Antiretrovirals****6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors**

	Level	Medicine	Dosage Form and Strength	Notes
116.	NP	Abacavir (ABC)	Oral liquid: 100 mg (as sulfate)/5 ml.	
			Tablet: 300 mg (as sulfate)	
117.	NP	Lamivudine (3TC)	Oral liquid: 50mg/5ml	
			Tablet:150mg	
118.	NP	Tenofovir disoproxil fumarate (TDF)	Tablet: 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	
119.	NP	Zidovudine (ZDV or AZT)	Capsule: 100 mg, 250 mg.	

			Oral liquid: 50 mg/5 ml. Solution for IV infusion injection: 10 mg/ml in 20-ml vial. Tablet: 100mg,300 mg.	
120.	NP	Entecavir	Tablet 0.5mg, 1mg	
121.	NP	Tenofovir + Emtricitabine	Tablet 300mg+ 200 mg	added on HPA request for the program

**6.4.2.2 Non-nucleoside reverse transcriptase inhibitors**

	Level	Medicine	Dosage Form and Strength	Notes
122.	NP	Efavirenz (EFV or EFZ)	Capsule: 50 mg, 100 mg,200 mg	
			Oral liquid: 150 mg/5 ml	
			Tablet: 600 mg	
123.	NP	Nevirapine (NVP)	Oral liquid: 50 mg/5 ml	
			Tablet: 200 mg	

**6.4.2.3 Protease inhibitors**

	Level	Medicine	Dosage Form and Strength	Notes
124.	NP	Lopinavir + ritonavir (LPV/r)	Capsule: 133.3 mg + 33.3 mg	
			Oral liquid: 400 mg + 100 mg/5 ml	
125.	NP	Nelfinavir (NFV)	Oral powder: 50 mg/g	
			Tablet or Tablet: 250 mg (as mesilate)	
126.	NP	Ritonavir	Oral liquid: 400 mg/5 ml	
			Capsule or Tablet:100mg	

**6.4.2.4 Fixed Dose Combinations**

	Level	Medicine	Dosage Form and Strength	Notes
127.	NP	Efavirenz + emtricitabine* + tenofovir	Tablet: 600 mg + 200 mg + 300 mg, * FTC is an acceptable alternative to 3TC; based on knowledge of the pharmacology; the resistance patterns and clinical trials of antiretrovirals	
128.	NP	Emtricitabine* + tenofovir	Tablet: 200 mg + 300 mg * FTC is an acceptable alternative to 3TC; based on knowledge of the pharmacology; the resistance patterns and clinical trials of antiretrovirals	
129.	NP	Zidovudine + lamivudine	Tablet: 300 mg + 150 mg	
130.	NP	Zidovudine + lamivudine + nevirapine	Tablet: 300 mg + 150 mg + 200mg	
131.	NP	Emtricitabine + Rilpivirine + Tenofovir	Tablets:600mg+300mg+200mg, 200mg+300mg+600mg	

**6.4.2.5 Medicines for Hepatitis (B and C)**

	Level	Medicine	Dosage Form and Strength	Notes
--	-------	----------	--------------------------	-------

132.	NP	Sofosbuvir	Tablet: 400mg	
133.	NP	Ledipasvir +Sofosbuvir	Tablet: 90mg + 400mg	
134.	NP	Daclatasvir	Tablet: 90mg	
135.	NP	Ribavarin	Capsule: 200mg	
136.	NP	Tenofovir	Tablet: 300mg	
137.	NP	Entacavir	Tablet: 0.5mg	

**6.5 Antimalarial medicines**

	Level	Medicine	Dosage Form and Strength	Notes
138.	NP	Mefloquine	Tablet: 250 mg	
139.	NP	Quinine	Tablet: 300mg, 100 mg Syrup:150mg/ml Injection:300 mg/ml 2ml, 80mg/ml	
140.	NP	Chloroquine	Tablet:150 mg	
141.	NP	Sulphadoxine + pyrimethamine	Tablet:500 mg + 25mg	
142.	NP	Primaquine	Tablet:7.5 mg,15 mg	
143.	NP	Artesunate	Tablet: 150 mg , Injection: 150 mg	
144.	NP	Artemether	Tablet: 80 mg Injection: 80 mg	
145.	NP	Proguanil	Tablet 100mg	
146.	NP	Doxycycline hyolate	Tablet: 100mg	

**6.5.1 Anti-pneumocystosis and antitoxoplasmosis**

	Level	Medicine	Dosage Form and Strength	Notes
147.	Sp	Sulphadiazine	Tablets: 500mg	
148.	Sp	Pyrimethamine	Tablet: 25mg	
149.	Sp	Spiramycin	Tablet: 1.5MIU, 3 MIU	
150.	P,S,T	Sulfamethoxazole + trimethoprim	Oral suspension: 200 mg + 40 mg/5 ml Tablet:100 mg + 20 mg, 400 mg + 80 mg	
151.	Sp	Folinic acid/Leucovorin	Tablet: 5mg, 10mg	

**6.5.2 Other Anti virals**

	Level	Medicine	Dosage Form and Strength	Notes
152.	T	Ribavarin	Tablet: 200, 400, 600mg Oral solution: 40mg/ml	
153.	T	Oseltamivir	Capsule: 30mg, 45mg, 75 mg Oral Syrup: 12mg/ml	

**7.ANTIMIGRAINE MEDICINE****7.1 For treatment of acute attack**

	Level	Medicine	Dosage Form and Strength	Notes
154.	P,S,T	Acetyl salicylic acid	Tablet:75mg ,150 mg, 300mg	
155.	P,S,T	Paracetamol	Oral liquid: 120 mg/5ml	

			Tablet: 500 mg Suppository: 125 mg, 250 mg, 500mg																					
156.	T	Sumatriptan	Tablet :25mg, 50mg																					
<b>7.2 For prophylaxis</b>																								
<table border="1"> <thead> <tr> <th></th><th>Level</th><th>Medicine</th><th>Dosage Form and Strength</th><th>Notes</th></tr> </thead> <tbody> <tr> <td>157.</td><td>P,S,T</td><td>Propranolol</td><td>Tablets: 5 mg, 10 mg, 40 mg</td><td></td></tr> <tr> <td>158.</td><td>S,T</td><td>Flunarizine</td><td>Tablets: 5 mg, 10 mg</td><td></td></tr> <tr> <td>159.</td><td>P,S,T</td><td>Topiramate</td><td>Tablet: 25mg and 50mg</td><td>Weight loss adverse reaction due to appetite suppression</td></tr> </tbody> </table>						Level	Medicine	Dosage Form and Strength	Notes	157.	P,S,T	Propranolol	Tablets: 5 mg, 10 mg, 40 mg		158.	S,T	Flunarizine	Tablets: 5 mg, 10 mg		159.	P,S,T	Topiramate	Tablet: 25mg and 50mg	Weight loss adverse reaction due to appetite suppression
	Level	Medicine	Dosage Form and Strength	Notes																				
157.	P,S,T	Propranolol	Tablets: 5 mg, 10 mg, 40 mg																					
158.	S,T	Flunarizine	Tablets: 5 mg, 10 mg																					
159.	P,S,T	Topiramate	Tablet: 25mg and 50mg	Weight loss adverse reaction due to appetite suppression																				

## 8. ANTINEOPLASTIC, IMMUNOSUPPRESSIVES AND MEDICINES USED IN PALLIATIVE CARE

### 8.1 Immunosuppressive medicines

	Level	Medicine	Dosage Form and Strength	Notes
160.	T	Azathioprine	Tablet: 50 mg	
161.	T	Cyclosporin	Capsule: 25 mg Injection 50 mg/ml	

### 8.2 Cytotoxic medicines

	Level	Medicine	Dosage Form and Strength	Notes
162.	T	Cisplatin	Injection: 50 mg/50 mL; 100 mg/100 mL.	Cervical cancer (as a radio-sensitizer);  Head and neck cancer (as a radio-sensitizer);  Nasopharyngeal cancer (as a radio-sensitizer);  Non-small cell lung cancer;  Osteosarcoma;  Ovarian germ cell tumour;  Testicular germ cell tumour
163.	T	Carboplatin	Injection: 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL	Early stage breast cancer;  Epithelial ovarian cancer;  Nasopharyngeal cancer; Non-small cell lung cancer;  Osteosarcoma;

				Retinoblastoma
164.	T	Cyclophosphamide	Powder for injection: 500 mg in vial  Tablet: 25 mg.	Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Early stage breast cancer; Gestational trophoblastic neoplasia; Hodgkin lymphoma; Follicular lymphoma; Rhabdomyosarcom; Ewing sarcoma; Acute lymphoblastic leukaemia; Burkitt lymphoma; Metastatic breast cancer
165.	T	Docetaxel	Injection 20 mg/ mL; 40 mg/ mL	Early stage breast cancer; Metastatic breast cancer; Metastatic prostate cancer
166.	T	Doxorubicin	Powder for injection: 10 mg; 50 mg (hydrochloride) in vial	Diffuse large B-cell lymphoma; Early stage breast cancer; Hodgkin lymphoma; Kaposi sarcoma; Follicular lymphoma; Metastatic breast cancer; Osteosarcoma; Ewing sarcoma; Acute lymphoblastic leukaemia; Wilms tumour; Burkitt lymphoma
167.	T	Filgrastim	Injection 300 mcg/0.5 ml	Primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemo therapy;  Secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemo therapy;  To facilitate administration of dose dense chemotherapy regimens
168.	T	Fluorouracil	Injection 50 mg/ mL in 5- mL ampoule	Early stage breast cancer; Early stage colon cancer;

				Early stage rectal cancer; Metastatic colorectal cancer; Nasopharyngeal cancer
169.	T	Gemcitabine	Powder for injection: 200 mg in vial, 1 g in vial	Epithelial ovarian cancer; Non-small cell lung cancer
170.	T	Methotrexate	Powder for injection: 50 mg (as sodium salt) in vial  Tablet: 2.5 mg (as sodium salt)	Early stage breast cancer; Gestational trophoblastic neoplasia;  Osteosarcoma; Acute lymphoblastic leukaemia;  Acute promyelocytic leukaemia
171.	T	Oxaliplatin	Injection: 50 mg/10 mL in 10- mL vial; 100 mg/20 mL in 20- mL vial	Early stage colon cancer; Metastatic colorectal cancer
172.	T	Paclitaxel	Powder for injection: 6 mg/ mL	Epithelial ovarian cancer; Early stage breast cancer; Metastatic breast cancer;  Kaposi sarcoma;  Nasopharyngeal cancer;  Non-small cell lung cancer;  Ovarian germ cell tumour
173.	T	Rituximab	Injection: 100 mg/10 mL in 10- mL vial	Diffuse large B-cell lymphoma;  Chronic lymphocytic leukaemia;  Follicular lymphoma
174.	T	Trastuzumab	Powder for injection: 60 mg; 150 mg; 440 mg in vial	Early stage HER2 positive breast cancer;  Metastatic HER2 positive breast cancer
175.	T	Vincristine	Powder for injection: 1 mg; 5 mg (sulfate) in vial.	Diffuse large B-cell lymphoma;  Gestational trophoblastic neoplasia;  Hodgkin lymphoma;  Kaposi sarcoma;  Follicular lymphoma;  Retinoblastoma;  Rhabdomyosarcoma;  Ewing sarcoma;

				Acute lymphoblastic leukaemia; Wilms tumour; Burkitt lymphoma
176.	T	Capecitabine	Tablet: 150 mg; 500 mg	Early stage colon cancer; Early stage rectal cancer; Metastatic breast cancer; Metastatic colorectal cancer
177.	T	Imatinib	Tablet: 100mg, 400mg	Chronic myeloid leukemia; Gastrointestinal stromal tumour

**8.3 Hormones and antihormones**

	Level	Medicine	Dosage Form and Strength	Notes
178.	Sp	Dexamethasone	Injection: 4 mg dexamethasone phosphate (as disodium salt) in 1-ml ampoule	
179.	Sp	Hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial	
180.	P,S,T	Prednisolone	Tablet: 5 mg, 20 mg, Syrup: 3mg/5ml	
181.	Sp	Tamoxifen	Tablet:10 mg, 20 mg (as citrate)	
182.	Sp	Betamethasone	Injection:6mg/ml	
183.	Sp	Fludrocortisone	Tablet: 0.1mg	
184.	S,T	Bromocriptin	Tablet: 2.5mg 5 mg	
185.	S,T	Cabergoline	Tablet: 0.25mg, 0.5mg	

**8.4 Medicines used in palliative care****8.4.1 Analgesics**

	Level	Medicine	Dosage Form and Strength	Notes
186.	P,S,T	Ibuprofen	Oral liquid: 100mg/5ml Tablet: 200 mg,400 mg	
187.	Sp	Morphine	Oral liquid: 10 mg (hydrochloride or sulfate)/5 ml Tablet: 10mg,30mg modified release (sulfate)	
188.	P,S,T	Paracetamol	Tablet: 500 mg Oral liquid: 120mg/5ml; 125mg/5ml	Antipyretic analgesic

**8.4.3 Anti-emetics**

	Level	Medicine	Dosage Form and Strength	Notes
189.	S,T	Ondansetron	Injection:4mg, 8mg in 2-ml ampoule Tablet: 4mg, 8mg Syrup: 2mg/5ml	

--	--	--	--

**8.4.4 Antispasmodics**

	Level	Medicine	Dosage Form and Strength	Notes
190.	P,S,T	Hyoscine butyl bromide	Injection: 20 mg/ml Tablet: 10mg	
191.	P,S,T	Simethicone	Tablet: 80 mg Drops: 20 mg Syrup: 2% emulsion 120 ml	

**8.4.5 Psychotherapeutic medicines**

	Level	Medicine	Dosage Form and Strength	Notes
192.	P,S,T	Amitriptyline	Tablet:10mg,25 mg (hydrochloride)	Tricyclic anti-depressant
193.	P,S,T	Midazolam	Injection:1mg/ml ,5mg/ml in 2ml ampoule (hydrochloride), Tablet: 7.5mg , Syrup: 2mg/ml	

**9. ANTIPARKINSONISM MEDICINES**

	Level	Medicine	Dosage Form and Strength	Notes
194.	Sp	Levodopa + Carbidopa	Tablet:100 mg + 10 mg	
195.	Sp	Trihexyphenidyl HCL	Tablet: 2 mg	
196.	T	Ropinirole	Tablet:0.5mg, 1mg , 2mg	

**10. MEDICINES AFFECTING THE BLOOD****10.1 Antianemia medicines**

	Level	Medicine	Dosage Form and Strength	Notes
197.	P,S,T	Ferrous salt	Oral solution: equivalent to 25 mg Elemental iron (as sulfate)/ml Tablet: equivalent to 60 mg iron	
198.	P,S,T	Ferrous salt + folic acid	Tablet: equivalent to 60 mg iron + 400 micrograms folic acid	nutritional supplement for use during pregnancy
199.	P,S,T	Folic acid	Tablet: 1mg, 5mg	
200.	T	Iron+ dextran	Injection :50mg iron /ml	
201.	T	Erythropoietin	Injection:2000IU/0.5ml	

**10.2 Medicines affecting coagulation**

	Level	Medicine	Dosage Form and Strength	Notes
202.	Sp	Heparin sodium	Injection: 1000 IU/ml, 5000 IU/ml,20000 IU/ml in 1-ml ampoule	
203.	Sp	Enoxaparin	injection: 40mg (equivalent to 4000 U), 60mg (equivalent to 6000 U) (sodium)	
204.	P,S,T	Phytomenadione (vitamin k1)	Injection:10 mg/ml in 5-ml ampoule	
205.	Sp	Protamine sulfate	Injection: 10 mg/ml in 5-ml	

			ampoule	
206.	Sp	Warfarin	Tablet: 1 mg; 2 mg and 5 mg (sodium salt)	
207.	T	Tranexamic acid	Tablet: 500mg,100mg Injection: 100mg/ml	

**11. BLOOD PRODUCTS AND PLASMA SUBSTITUTES****11.1 Plasma substitutes**

	Level	Medicine	Dosage Form and Strength	Notes
208.	Sp	Dextran	Injectable solution: Dextran 40, dextran 70	

**11.2 Plasma fractions for Specific use**

	Level	Medicine	Dosage Form and Strength	Notes
209.	Sp	Human normal immunoglobulin	Human normal immunoglobulin (intramuscular) administration: 16% protein solution. Intravenous administration: 5%; 10% protein solution.20%	
210.	Sp	Fresh Frozen Plasma(FFP)	Injection	
211.	Sp	Cryoprecipitate	Injection	
212.	Sp	Factor viii concentrate	Injection (dried)	
213.	Sp	Factor ix	Injection (dried)	
214.	Sp	Albumin	Injection :5% and 20%	

**11.3 Blood product**

	Level	Medicine	Dosage Form and Strength	Notes
215.	P,S,T	Blood	Whole blood and packed cells	
216.	Sp	Platelet concentrate		

**12. CARDIOVASCULAR MEDICINES****12.1 Antianginal medicines**

	Level	Medicine	Dosage Form and Strength	Notes
217.	P,S,T	Glyceryl trinitrate	Injection: 5 mg/ml Tablet(sublingual): 500 micrograms	
218.	P,S,T	Isosorbide dinitrate	Tablet: 5 mg,10mg	
219.	P,S,T	Metoprolol	Tablet: 25mg, 50 mg, Injection :5mg	
220.	P,S,T	Verapamil	Tablet: 40 mg, 80 mg (hydrochloride)	
221.	T	Sildenafil	Tablet: 20mg Syrup: 10mg/1ml	Commonly used for primary pulmonary hypertension
222.	S,T	Nitroglycerine	Ointment: 0.2%	
223.	S,T	Diltiazem	Injection: 25mg/5ml Ointment:2%	

224.	P,S,T	Diosmine + Hisperidine	Tablet :500mg	Use in hemorrhoids and varicose veins
------	-------	------------------------	---------------	---------------------------------------

**12.2 Antiarrhythmic medicines**

	Level	Medicine	Dosage Form and Strength	Notes
225.	S,T	Adenosine	Injection: 3mg/ml in physiological saline in 2ml ampoule	For termination of supra ventricular tachycardia
226.	S,T	Amiodarone	Injection:50mg/ml in 10ml Tablet: 100mg, 200mg	
227.	S,T	Digoxin	Injection: 250 micrograms/ml in 2-ml ampoule Oral solution: 50 micrograms/ml Tablet: 62.5 micrograms; 250 micrograms	
228.	S,T	Isoprenaline	Injection: 2mg (hydrochloride)/ml in ampoule	For symptomatic bradycardia
229.	S,T	Lidocaine	Injection: 20 mg (hydrochloride)/ml in 5-ml ampoule	
230.	S,T	Verapamil	Injection: 2.5 mg (hydrochloride)/ml in 2-ml ampoule (hydrochloride) Tablet: 40 mg,80 mg	

**12.3 Antihypertensive medicines**

	Level	Medicine	Dosage Form and Strength	Notes
231.	P,S,T	Amlodipine	Tablet: 2.5mg, 5mg	
232.	S,T	Labetolol	Tablet: 100mg,200mg,300mg.Injection: 5mg/ml	
233.	P,S,T	Enalapril	Tablet: 2.5 mg, 5mg .Injection 1.25mg/ml	
234.	S,T	Hydralazine*	Injection: 20 mg/ml (hydrochloride) in ampoule *For use in the acute management of severe pregnancy-induced hypertension only Tablet: 25 mg,50 mg	
235.	P,S,T	Hydrochlorothiazide	Tablet : 25 mg, 12.5 mg	
236.	P,S,T	Losartan potassium	Tablet: 25 mg, 50mg	
237.	S,T	Methyldopa*	Tablet: 250 mg, 500mg *For use in the management of pregnancy-induced hypertension only.	
238.	T	Sodium nitroprusside	Powder for infusion: 50 mg/5ml in ampoule	Used in hypertensive emergencies.

<b>12.4 Medicines used in heart failure</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
239.	P,S,T	Digoxin	Injection: 250 micrograms/ml in 2-ml ampoule	
			Oral solution: 50 micrograms/ml	
			Tablet: 62.5 micrograms, 250 micrograms	
240.	S,T	Dopamine	Injection: 40 mg (hydrochloride) in 5-ml vial	
241.	S,T	Carvedilol	Tablet: 3.125mg, 6.25mg	
242.	P,S,T	Enalapril	Tablet: 2.5 mg, 5mg	
243.	P,S,T	Furosemide	Injection: 10mg/ml in 2 ml vials	
			Tablet: 20mg, 40mg	
244.	P,S,T	Hydrochlorothiazide	Tablet scored): 25 mg ,12.5mg	
245.	Sp	Dobutamine	Injection 250mg/5ml	It is used in patients who do not tolerate dopamine

**12.5 Antithrombotic medicines**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
246.	P,S,T	Acetylsalicylic acid	Tablet: 75mg,100 mg	
247.	P,S,T	Clopidogrel	Tablets:75 mg	
248.	S,T	Streptokinase	Powder for injection:1.5 million IU in vial	
249.	S,T	Alteplase	Injection: 20mg, 30mg, 50mg	For pulmonary embolism

**12.6 Lipid-lowering agents**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
250.	P,S,T	Atorvastatin	Tablet: 5mg,10 mg, 20mg	

**12.7 Other vascular medicines**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
251.	T	Terlipressin	Injection: 1mg, 2mg	
252.	T	Octreotide	Injection:50mg, 100mg	Control variceal bleedings

**13. DERMATOLOGICAL MEDICINES****13.1 Antifungal medicines**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
253.	P,S,T	Clotrimazole + Betamethasone	Cream: 0.025% + 1%,	
254.	P,S,T	Clotrimazole	Cream and solution, oral paint	
255.	P,S,T	Ketoconazole	Cream	

**13.2 Anti-infective medicines**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
256.	P,S,T	Povidone Iodine	Ointment and cream: 5%w/w	

257.	P,S,T	Potassium permanganate	Solution (aqueous): 1in10;000, crystals, powder	
258.	P,S,T	Silver sulfadiazine	Cream: 1%	
259.	P,S,T	Acyclovir	Cream: 5%, Ointment: 5%	
260.	P,S,T	Mupirocin	Ointment, Cream	
261.	P,S,T	Fusidic Acid	Ointment , Cream	

**13.3 Anti-inflammatory and antipruritic medicines**

	Level	Medicine	Dosage Form and Strength	Notes
262.	P,S,T	Betamethasone	Ointment / cream: 0.1%,0.05% (as dipropionate)	
263.	P,S,T	Hydrocortisone	Ointment or cream: 0.5%,1% (acetate)	
264.	P,S,T	Triamcinolone	Injection: 10mg, 40mg (acetonide)	
			Oral gel	
265.	P,S,T	Calamine	Lotion	

**13.4 Astringent medicines**

	Level	Medicine	Dosage Form and Strength	Notes
266.	P,S,T	Zinc oxide	Paste, Cream, Powder	

**13.5 Medicines affecting skin differentiation and proliferation**

	Level	Medicine	Dosage Form and Strength	Notes
267.	S,T	Benzoyl peroxide	Lotion and gel: 2.5% , 5%	
268.	P,S,T	Coal tar	Lotion	
269.	S,T	Podophyllum resin	Solution: 10, 25%	
270.	S,T	Salicylic acid	Solution: 5%, Ointment 20%	
271.	S,T	Urea	Ointment and cream: 10%	
272.	S,T	White paraffin	Cream, liquid	
273.	P,S,T	Tretinoin	Cream: 0.025%	

**13.6 Scabicides and pediculicides**

	Level	Medicine	Dosage Form and Strength	Notes
274.	P,S,T	Benzyl benzoate	Lotion: 25%	
275.	S,T	Permethrin	Cream: 5% for (scabies),1% for lice treatment	
			Lotion: 5% for (scabies),1% for lice treatment	

**14. DIAGNOSTIC AGENTS****14.1 Radio contrast media**

	Level	Medicine	Dosage Form and Strength	Notes
276.	Sp	Amidotrizoate (urograffin 60%, 76%)	Injection: 140-420 mg iodine (as sodium or meglumine salt)/ml in 20-ml ampoule	
277.	Sp	Barium sulfate	Aqueous suspension/powder	
278.	Sp	Iohexol	Injection: 140 –350 mg iodine/ml in 5-ml, 10-ml and 20-ml ampoule	
279.	Sp	Gastrografin (Sodium)	Oral solution: 660mg in 1 ml,	

		amidotrizoate + Meglumine amidotrizoate)	100mg in 1 ml Rectal solution:	
280.	Sp	Gadolinium containing contrast for MRI	Injection:287mg/ml	

**14.2 OTHERS**

	Level	Medicine	Dosage Form and Strength	Notes
281.	Sp	Methylene blue	Aqueous solution	for diagnostic purposes in gynaecology

**15. DISINFECTANTS AND ANTISEPTICS****15.1 Antiseptics**

	Level	Medicine	Dosage Form and Strength	Notes
282.	P,S,T	Chlorhexidine	Solution: 5%	
283.	P,S,T	Ethanol	Solution: 70% (denatured)	
284.	P,S,T	Hydrogen Peroxide	Solution: 6%	
285.	P,S,T	Povidone iodine	Solution: 5, 10%	
286.	P,S,T	Chlorozylénol (dettol)	Cream: 4.8%	

**15.2 Disinfectants**

	Level	Medicine	Dosage Form and Strength	Notes
287.	P,S,T	Chlorine base compound	Powder: (0.1% available chlorine) for solution	
288.	P,S,T	Formaldehyde	Solution	

**16. DIURETICS**

	Level	Medicine	Dosage Form and Strength	Notes
289.	P,S,T	Furosemide	Injection: 10 mg/ml in 2-ml ampoule	
			Tablet: 40 mg	
290.	P,S,T	Hydrochlorothiazide	Tablet: 12.5mg , 25 mg,50 mg	
291.	P,S,T	Mannitol	Injectable solution:10%, 20%	
292.	P,S,T	Spironolactone	Tablet: 25 mg,50mg	
293.	P,S,T	Torsemide	Tablet: 5mg , 10mg, 20mg, 100mg.	Used in chronic renal failure as alternative to furosemide
			Injection: 10mg/ml	
294.	P,S,T	Metolazone	Tablet: 2.5mg, 5mg,10mg	Used in chronic renal failure as alternative to furosemide

**17. GASTROINTESTINAL MEDICINES****17.1 Antacids and other antiulcer medicines**

	Level	Medicine	Dosage Form and Strength	Notes
295.	P,S,T	Aluminium-Magnesium	Tablet: 200mg + 200mg,400mg +	

		based antacid	400mg (hydroxide) Oral liquid: 40mg/ml+ 40mg/ml	
296.	P,S,T	Ranitidine	Injection: 25 mg/ml in 2-ml ampoule Oral liquid: 75 mg/5-ml Tablet: 150 mg (as hydrochloride)	
297.	P,S,T	Pantoprazole	Tablet: 40mg, 20mg Injection: 40mg	Alternative : omeprazole
298.	P,S,T	Sucralfate	Syrup: 1000mg/10ml	
299.	P,S,T	Simethicone	Tablet: 80 mg Drops: 20 mg Syrup: 2% emulsion 120 ml	
300.	P,S,T	Ursodeoxycholic Acid	Tablet: 150 mg, 300 mg	
301.	P,S,T	Sodium Alginate + Magnesium Alginate	Syrup Powder	

**17.2 Antiemetic medicines**

	Level	Medicine	Dosage Form and Strength	Notes
302.	P,S,T	Domperidone	Oral liquid: 5mg /5ml Tablet: 10 mg	
303.	P,S,T	Metoclopramide	Injection: 5 mg (hydrochloride)/ml in 2-ml ampoule Tablet: 10 mg (hydrochloride) Syrup: 5mg/5ml	
304.	S,T	Ondansetron	Injection:2mg/ml in 2-ml ampoule Tablet: 4mg,8mg syrup 2mg/5ml	
305.	P,S,T	Promethazine	Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule Oral liquid: 5 mg (hydrochloride)/5 ml Tablet: 10 mg, 25 mg (hydrochloride)	
306.	P,S,T	Doxylamine +Pyridoxine	Tablet 10mg +10mg	For pregnancy
307.	P,S,T	Prochlorperazine	Injection: 12.5mg/ml ampoule	

**17.3 Antispasmodic medicines****17.4 Laxatives**

	Level	Medicine	Dosage Form and Strength	Notes
308.	P,S,T	Bisacodyl	Tablet: 5 mg Suppository: 10mg	
309.	P,S,T	Glycerin	Suppository: paediatric , adult	

310.	P,S,T	Lactulose	Oral suspension: 667mg/ml	
311.	P,S,T	Sodium phosphate monohydrate +Sodium phosphate hepta hydrate	Disposable Enema	

**17.5 Medicines used in diarrhoea**

	Level	Medicine	Dosage Form and Strength	Notes
312.	P,S,T	Oral rehydration salts * (for glucose-electrolyte solution)	glucose: 75 mEq sodium: 75 mEq or mmol/l chloride: 65 mEq or mmol/l potassium: 20 mEq or mmol/l citrate: 10 mmol/l osmolarity: 245 mOsm/l glucose: 13.5 g/l sodium chloride: 2.6 g/l potassium chloride: 1.5 g/l trisodium citrate dihydrate: 2.9 g/l * in cases of cholera a higher concentration of sodium may be required	
313.	P,S,T	Elemental Zinc (sulphate )	Oral liquid: in 10 mg per unit dosage forms. * In acute diarrhoea zinc sulfate should be used as an adjunct to oral rehydration salts. Tablet: in 10 mg per unit dosage forms.	

**18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES****18.1 Adreno-cortical hormones**

	Level	Medicine	Dosage Form and Strength	Notes
314.	P,S,T	Hydrocortisone	Powder for injection: 100 mg/ml(as sodium succinate) in vial	
315.	S,T	Dexamethasone	Injection: 4mg as disodium salt in 1ml ampoule Tablets: 0.5mg	
316.	S,T	Methylprednisolone	Injection: 20mg/ml,40mg/ml,80mg/ml, Tablet: 2mg, 4mg	

317.	P,S,T	Prednisolone	Oral liquid: 5mg/5ml Tablets: 5 mg, 20 mg	
------	-------	--------------	----------------------------------------------	--

**18.2 Androgens**

	Level	Medicine	Dosage Form and Strength	Notes
318.	Sp	Testosterone	Capsule :40mg	
			Injection:100mg/ml, 200mg/ml	
319.	P,S,T	Danazol	Tablet: 100mg, 200mg	

**18.3 Contraceptives****18.3.1 Hormonal contraceptives**

	Level	Medicine	Dosage Form and Strength	Notes
320.	P,S,T	Ethinylestradiol + levonorgestrel	Tablet: 30 micrograms + 150 micrograms	
321.	P,S,T	Ethinylestradiol + norethisterone	Tablet: 35 micrograms + 1.0 mg	
322.	S,T	Medroxyprogesterone acetate	Depot injection: 150 mg/ml in 1-ml vial	

**18.3.2 Intrauterine devices/Implants**

	Level	Medicine	Dosage Form and Strength	Notes
323.	Sp	Copper-containing device	IUCD ( CopperT 380)	
324.	Sp	Levonorgestrel (Mirena)	IUD	
325.	Sp	Etonogetrel (Implanon)	Implant: 68mg	

**18.3.3 Barrier methods**

	Level	Medicine	Dosage Form and Strength	Notes
326.	P,S,T	Condoms		

**18.4 Estrogens**

	Level	Medicine	Dosage Form and Strength	Notes
327.	P,S,T	Ethinylestradiol	Tablet: 10 micrograms, 50 micrograms	
328.	S,T	Estrogen	Cream	
329.	S,T	Lynestrenol	Tablet:0.5mg	
330.	S,T	Levonorgestrel	Tablet: 0.75mg	

**18.4.1 Estrogen combinations for polycystic ovary syndrome**

	Level	Medicine	Dosage Form and Strength	Notes
331.	Sp	Ethinylestradiol + cypoterone acetate	Tablet: 35 microgram + 2 mg (21 tablets packs)	

**18.5 Insulins and other medicines used for diabetes**

	Level	Medicine	Dosage Form and Strength	Notes
332.	P,S,T	Insulin injection (soluble )	Injection: 40 IU/ml in 10-ml vial, 100 IU/ml in 10-ml vial	
333.	P,S,T	Intermediate-acting insulin (human)	Injection: 40 IU/ml in 10 ml vial, 100 IU/ml in 10 ml vial (as compound insulin zinc suspension or isophane insulin)	
334.	S,T	Insulin glargine	injection	
335.	P,S,T	Premix insulin	Injection:30:70 40IU/ml	
336.	S,T	Acarbose (starch,	Tablet: 25mg, 50mg, 100mg	

		microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide)		
337.	S,T	Sitagliptin	Tablet	
338.	P,S,T	Metformin	Tablet: 500 mg, 850mg, 1000mg SR (hydrochloride)	
339.	S,T	Glucagon	Injection 1mg/ml	
340.	P,S,T	Glimepiride	Tablet: 1mg, 2mg , 3mg, 4mg	

**18.6 Ovulation inducers**

	Level	Medicine	Dosage Form and Strength	Notes
341.	S,T	Clomiphene	Tablet: 25mg,50 mg, 100mg (citrate)	
342.	S,T	Human Chorionic Gonadotropin(HCG)	Injection: 5000IU, 10000IU	

**18.7 Progestogens**

	Level	Medicine	Dosage Form and Strength	Notes
343.	T	Dydrogesterone	Tablets: 10 mg	
344.	T	Medroxyprogesterone	Tablets: 2.5 mg; 10 mg	
345.	T	Micronised progesterone	Oral Tablet: 25 mg, 75 mg, 100mg, 200mg	

**18.8 Thyroid hormones and antithyroid medicines**

	Level	Medicine	Dosage Form and Strength	Notes
346.	P,S,T	Levothyroxine	Tablet: 25 micrograms,50 micrograms,75 microgram,100 micrograms (sodium salt)	Under supervision of a specialist
347.	S,T	Propylthiouracil	Tablet: 50 mg	
348.	P,S,T	Carbimazole	Tablet (film coated): 5 mg , 10mg	Under supervision of a specialist

**19. IMMUNOLOGICALS****19.1 Diagnostic agents**

All tuberculins should comply with the WHO Requirements for Tuberculins (Revised 1985). WHO Expert Committee on Biological Standardization 36th report; (WHO Technical Report Series; No. 745; 1987; Annex 1).

	Level	Medicine	Dosage Form and Strength	Notes
349.	S,T	Tuberculin: purified protein derivative (PPD)	Injection: 5 TU , 10 TU	

**19.2 Sera and immunoglobulin**

All plasma fractions should comply with the WHO Requirements for the Collection; Processing and Quality Control of Blood; Blood Components and Plasma Derivatives (Revised 1992). WHO Expert Committee on Biological Standardization Forty-third report

	Level	Medicine	Dosage Form and Strength	Notes
350.	S,T	Anti-D immunoglobulin (human)	Injection: 300 micrograms in single-dose vial	
351.	P,S,T	Anti-tetanus immunoglobulin (human)	Injection: 250 IU ,500IU	

352.	S,T	Hepatitis B immunoglobulin (HBIG)	Injection 200U/ml	
353.	T	IV immunoglobulin (IVIG)	Injection 2.5g/vial, 5g/vial, 10g/vial	
354.	S,T	Varicella immunoglobulin (VZIG)	Injection 125 IU	

**19.3 Vaccines: All vaccines should comply with the WHO Requirements for Biological Substances.****19.3.1 For universal immunization**

	Level	Medicine	Dosage Form and Strength	Notes
355.	NP	BCG vaccine		
356.	NP	Hepatitis B vaccine		
357.	NP	Measles vaccine		
358.	NP	Polio vaccine- Oral (m OPV)		
359.	NP	Polio vaccine- Oral (b OPV)		
360.	NP	Polio vaccine-Inactivated (IPV)		
361.	NP	Diphtheria, pertussis, tetanus vaccine		
362.	NP	Diphtheria-Tetanus-Pertussis (whole cell)-Hepatitis B-Homophiles influenza type b		
363.	NP	Measles, mumps, rubella vaccine		
364.	NP	Measles + Rubella		added as per request from the National program
365.	NP	Diphtheria + Tetanus		added as per request from the National program
366.	NP	HiB Vaccine		added as per request from the National program
367.	NP	Td		added as per request from the National program

**19.3.2 For Specific groups of individuals**

	Level	Medicine	Dosage Form and Strength	Notes
368.	SP	Influenza vaccine (inactivated)		
369.	SP	Meningococcal meningitis vaccine		
370.	SP	Yellow fever vaccine		
371.	SP	Typhoid vaccine		
372.	SP	Cholera vaccine		

373.	SP	Hepatitis A vaccine		
374.	SP	Varicella vaccine		
375.	SP	Human Papilloma virus(HPV)	Bivalent+ quadrivalent	added as per the request from the program
376.	SP	Pneumococcal polysaccharide vaccine		added as per the request from the program
377.	SP	Pneumococcal conjugated vaccine		
378.	SP	HiB Vaccine		

**20. MUSCLE RELAXANTS AND CHOLINESTERASE INHIBITORS**

	Level	Medicine	Dosage Form and Strength	Notes
379.	S,T	Atracurium	Injection: 10 mg/ml	
380.	S,T	Neostigmine	Injection: 500 mcg in 1-ml ampoule, 250 mcg (metilsulfate) in 1-ml ampoule	
381.			Tablet: 15 mg (bromide)	
382.	S,T	Suxamethonium	Injection: 50 mg (chloride)/ml in 2-ml ampoule	
383.	S,T	Pyridostigmine	Injection: 1 mg in 1-ml ampoule Tablet: 60 mg (bromide)	
384.	S,T	Rocuronium	Injection: 50mg/5ml	
	S,T	Baclofen	Tablet: 10mg	For spasticity of cerebral origin

**21. OPHTHALMOLOGICAL PREPARATIONS****21.1 Anti-infective agents**

	Level	Medicine	Dosage Form and Strength	Notes
385.	P,S,T	Chloramphenicol	Solution (eye drops): 0.5%	Used by ophthalmologists for corneal abrasions and post operation.
			Ointment: 1%	
386.	P,S,T	Gentamicin	Solution(eye drops): 0.3% (sulfate)	
387.	P,S,T	Aciclovir	Ointment: 3%;	
388.	P,S,T	Ciprofloxacin	Eye drops, eye ointment 0.3%	
389.	P,S,T	Tobramycin	Eye drops, eye ointment	
390.	S,T	Tobramycin + dexamethasone	Eye drops	
391.	P,S,T	Fluconazole	Eye drops: 0.3%	

392.	P,S,T	<b>Natamycin</b>	Eye drops: 0.3%	
<b>21.2 Anti-inflammatory agents</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
393.	P,S,T	Prednisolone	Solution (eye drops): 0.5% (sodium phosphate)	
394.	P,S,T	Dexamethasone	eye drops	
395.	S,T	Nepafenac	Eye drop	
<b>21.3 Local anaesthetics</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
396.	S,T	Tetracaine	Solution (eye drops): 0.5% (hydrochloride)	
397.	P,S,T	Lidocaine	4% topical solution	
398.	P,S,T	Propacaine	Eye drops: 0.5%	
<b>21.4 Miotics and antiglaucoma medicines</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
399.	S,T	Acetazolamide	Tablet:250 mg	
400.	S,T	Pilocarpine	Solution (eye drops); 2%; 4% (hydrochloride or nitrate)	
401.	S,T	Timolol	Solution (eye drops): 0.25%, 0.5% (as maleate)	
<b>21.5 Mydriatics</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
402.	P,S,T	Phenylephrine	Solution (eye drops):0.12%	
403.	T	Cyclopentolate	Eye drops 1%	Potential systemic toxicity in children and to be removed from P,S
404.	P,S,T	Tropicamide	Eye drops: 0.5%, 1%	
<b>21.6 Medicines for allergic conditions</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
405.	P,S,T	Olopatadine	Eye solution: 0.1%	
<b>21.7 Ocular lubricant</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
406.	P,S,T	Tears natural	Solution (eye drops): dextran 70.1% hypromellose 0.3%	
407.	P,S,T	Hypromellose	Gel	
<b>21.8 Ophthalmic surgical aids</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
408.	T	Hydroxy propyl methyl cellulose	Solution:2%	
409.	T	Pilocarpine nitrate	Injection:0.5%	
410.	T	Trypan Blue	Solution:0.06%	
<b>21.9 Other Ophthalmic preps</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
411.	T	Sodium chloride (hypersol)	Solution: 5%	

**22. MEDICINES ACTING ON THE GENITOURINARY TRACT****22.1 Oxytocics**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
412.	P,S,T	Oxytocin	Injection:5IU/ml ,10 IU in 1-ml ampoule	
413.	S,T	Mifepristone	Tablet: 200 mg	
414.	S,T	Misoprostol	Tablet: 25mcg, 50mcg,100 mcg , 200 mcg	
415.	S,T	Ergometrine	Injection: 200 micrograms (hydrogen maleate) in 1-ml ampoule	note: methyl ergometrine
416.	S,T	PGF2 alpha (Carboprost)	Injection: 250mcg	
417.	S,T	PGE2 (Dinoprostone)	Injection: 0.5%	
418.	S,T	Valethamate	Injection: 8mg	

**22.2 Antioxytoxics (tocolytics)**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
419.	S,T	Nifedipine	Capsule/Tablet:10mg , retard 10mg, 20mg	
420.	S,T	Isoxsuprine	Tablet: 10mg,10mg retard Injection: 10mg/ml	

**22.3 Medicines for benign prostatic hyperplasia**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
421.	P,S,T	Finasteride	Tablet: 1mg, 5mg	
422.	S,T	Prazosin	Tablet:2mg	
423.	S,T	Tamsulosin	Capsule: 0.4mg	

**22.4 urinary antispasmodics**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
424.	Sp	Oxybutynin	Tablet: 2.5mg, 5mg	

**22.5 Urine alkalinizing agent**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
425.	P,S,T	Sodium Citrate + Citric acid	Sachet, Syrup	

**23. DIALYSIS SOLUTION**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
426.	S,T	Haemodialysis concentrate	Parenteral solution	
427.	S,T	Peritoneal dialysis concentrate	Solution	

<b>24. PSYCHOTHERAPEUTIC MEDICINES</b>				
<b>24.1 Medicines used in psychotic disorders</b>				
	Level	Medicine	Dosage Form and Strength	Notes
428.	P,S,T	Chlorpromazine	Oral liquid: 25 mg (hydrochloride)/5ml	
			Tablet: 100 mg (hydrochloride)	
429.	P,S,T	Fluphenazine	Injection: 25 mg (decanoate or enantate) in 1-ml ampoule	
430.	S,T	Haloperidol	Injection: 5 mg in 1-ml ampoule, 50mg /ml depo	
			Tablet: 2 mg, 5 mg	
431.	S,T	Olanzapine	Tablet: 2.5mg, 5mg	
432.	S,T	Risperidone	Tablet: 1mg, 2mg,	
			Oral liquid: 1mg/ml	
			Injection : Depo	
433.	T	Quetiapine	All strengths in ADL	
434.	S,T	Clozapine	Tablet 25 mg - 200 mg	To added as per the request of the Psychiatrist
<b>24.2 Medicines used in mood disorders</b>				
<b>24.2.1 Medicines used in depressive disorders</b>				
	Level	Medicine	Dosage Form and Strength	Notes
435.	P,S,T	Amitriptyline	Tablet: 10mg,25 mg (hydrochloride)	
436.	P,S,T	Fluoxetine	Capsules/tablet: 10mg, 20mg, Syrup: 20mg/5ml	
437.	P,S,T	Imipramine	Tablets:25mg	
438.	P,S,T	Escitalopram	Tablet:5mg,10mg,	
439.	S,T	Mirtazapine	Tablet :15mg	Non tricyclic antidepressant
440.	T	Venlafaxine	Tablet :25mg, 37.5mg,75mg	Non Tricyclic antidepressant
<b>24.2.2 Medicines used in bipolar disorders</b>				
	Level	Medicine	Dosage Form and Strength	Notes
441.	P,S,T	Carbamazepine	Tablets (scored): 100 mg, 200 mg	
442.	P,S,T	Valproic acid	Tablet (enteric coated): 200 mg, 500 mg (sodium salt)	
443.	T	Lithium	Tablet: 300mg,450 mg	
444.	S,T	Lamotrigine	Tablet:25mg, 100mg	
<b>24.3 Medicines used in generalized anxiety and sleep disorders</b>				
	Level	Medicine	Dosage Form and Strength	Notes
445.	P,S,T	Alprazolam	Tablet: 0.25 mg, 0.5mg	
446.	P,S,T	Diazepam	Tablet (scored): 2 mg, 5 mg	
447.	S,T	Chlordiazepoxide	Tablet: 10mg	

**24.4 Medicines used for obsessive compulsive disorders and panic attacks**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
448.	T	Clomipramine	Capsules: 10 mg, 25 mg (hydrochloride)	
449.	T	Fluvoxamine	Tablet:50mg , 25mg ,100mg	

**24.5 Medicines used in substance dependence programs**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
450.	NP	Methadone	Concentrate for oral liquid:5mg/ml; 10mg/ml (hydrochloride)  oral liquid: 5mg/5ml;10mg/5ml (used under restricted program only)	
451.	P,S,T	Nicotine replacement therapy (NRT)	Chewing gum: 2 mg; 4 mg (as polacrilex).	
			Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs.	
452.	S,T	Clonidine	Tablet: 75mcg,100mcg ,150mcg	Frequently used in renal failure patients
453.	T	Naltrexone	Tablet:50mg	

**24.6 Medicine used in child psychiatry**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
454.	SP	Atomoxetine	Tablet / capsules: 10mg,18mg, 25mg	

**24.7 Others**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
455.	T	Donepezil	Tablet:5mg	

**25. MEDICINES ACTING ON THE RESPIRATORY TRACT****25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
456.	P,S,T	Beclometasone	Inhalation (aerosol): 50 micrograms per dose (dipropionate); 250 micrograms (dipropionate) per dose	
457.	P,S,T	Epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule	
458.	P,S,T	Ipratropium bromide	Inhalation (aerosol): 20 micrograms/metered dose,	
459.	P,S,T	Salbutamol	Inhalation (aerosol):100 micrograms (as sulfate) per dose	
			Injection: 0.5mg(as sulfate)/ml	

			Respirator solution for use in nebulizers: 5 mg (as sulfate)/ml Tablet: 2 mg, 4 mg (as sulfate)	
460.	P,S,T	Theophylline	Tablet	Requires therapeutic monitoring for blood concentration

**26. CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES**

	Level	Medicine	Dosage Form and Strength	Notes
461.	P,S,T	Oral rehydration salts (for glucose-electrolyte solution)	see section 17.6	
462.	P,S,T	Glucose	Injectable solution: 5%, 10% isotonic, 25%,50% hypertonic	
463.	S,T	Glucose with sodium chloride	Injectable solution: 4% glucose, 0.18% sodium chloride (equivalent to Na+ 30 mmol/l; Cl- 30 mmol/l)	
464.	P,S,T	Glucose with sodium chloride	Injectable solution: 5% glucose; 0.9% sodium chloride (equivalent to Na+ 154 mmol/l; Cl- 154 mmol/l)	
465.	P,S,T	Glucose with sodium chloride	Injectable solution: 5% glucose; 0.45% sodium chloride (equivalent to Na+ 154 mmol/l; Cl- 154 mmol/l) ( to check )	
466.	P,S,T	Potassium chloride	Injectable solution Tablet: 600mg , Syrup	
467.	P,S,T	Sodium chloride	Injectable solution: 0.9% isotonic (equivalent to Na+ 154 mmol/l; Cl- 154 mmol/l) , 3%	
468.	P,S,T	Sodium hydrogen carbonate (Sodium bicarbonate)	Injectable solution: 1.4% isotonic (equivalent to Na+ 167 mmol/l; HCO3- 167 mmol/l); solution; 7.5% in 10-ml ampoule (equivalent to Na+ 1000 mmol/l; HCO3-1000 mmol/l), sachets, tablets	
469.	P,S,T	Sodium lactate; compound solution (Ringer Lactate)	Injectable solution	
470.	P,S,T	Water for injection	2-ml; 5-ml; 10-ml ampoules	

<b>27. VITAMINS AND MINERALS</b>				
	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
471.	T	Alfacalcidol	Tablet:0.25mg,	
472.	T	Cholecalciferol	Granules/sachets	
473.	P,S,T	Ascorbic acid	Tablet:500 mg	
474.	P,S,T	Pyridoxine	Tablet:10mg, 40mg	
475.	NP,T	Retinol	Sugar-coated tablet; 10 000 IU (as palmitate) (5.5 mg); capsule;200 000 IU (as palmitate) (110 mg); oral oily solution 100 000 IU (as palmitate)/ml in multidose dispenser; water-miscible injection 100 000 IU (as palmitate) (55 mg) in 2-ml ampoule	
476.	P,S,T	Vitamin B complex	Capsule: Vit B 1 mg, Vit B2 1 mg Tablet: Vit B 1 mg, Vit B2 1 mg	
477.	S,T	Thiamine	Tablet: 75mg. Injection 100mg	
478.	S,T	Calcium gluconate	Injection:100mg/ml in 10 ml ampoule	

## **28. MEDICINE USED FOR EAR, NOSE AND OROPHARYNX**

### **28.1 Ear**

#### **28.1.1 Anti - infective agents and anti - infective agents with corticosteroids**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
479.	P,S,T	Clotrimazole	Solution ( ear drops)	
480.	P,S,T	Clotrimazole + hydrocortisone	Solution ( ear drops)	
481.	P,S,T	Ciprofloxacin	Solution eye/ear drops 0.3%, eye ointment	
482.	S,T	Oflloxacin + dexamethasone	Solution eye/ear drops	

#### **28.1.2 Medicines for vestibular disorders**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
483.	P,S,T	Cinnarazine	Tablet: 5 mg,25mg	
484.	P,S,T	Prochlorperazine	Injection: 12.5mg/ml ampoule	To be added to anti-emetics

### **28.2 Nose**

#### **28.2.1 Corticosteroids**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
485.	P,S,T	Beclometasone	Solution (nasal Spray)	

#### **28.2.2 Decongestants**

	<b>Level</b>	<b>Medicine</b>	<b>Dosage Form and Strength</b>	<b>Notes</b>
486.	P,S,T	Oxymetazoline	Solution (nose drops): 0.05%.	

			0.025%	
487.	P,S,T	Normal saline	0.9% solution for nasal use	

**28.3.2 local anaesthetics**

	Level	Medicine	Dosage Form and Strength	Notes
488.	Sp	Lidocaine	Sprays: 4%	

**29. Specific medicines for Neonatal Care**

	Level	Medicine	Dosage Form and Strength	Notes
489.	Sp	Caffeine Citrate	Injection 20mg/ml ( equivalent to 10mg caffeine base/ml )	
			Oral liquid 20mg/ml ( equivalent to 10mg caffeine base/ml )	
490.	Sp	Ibuprofen	Injection 5mg/ml	
491.	Sp	Prostaglandins E	Solution for injection prostaglandin E1 0.5mg/ml in alcohol, prostaglandin E2 1mg/ml	
492.	Sp	Surfactants	Suspension for intra-tracheal instillation 25mg/ml and 80mg/ml	
493.	Sp	Aminophylline	injection: 25mg/ml in 10ml ampoule	For apnea for premature babies
494.	Sp	Intra lipid	Solution: 20% (TPN)	For preterm nutrition
495.	Sp	Amino Acid	Infant solution: 10% (TPN)	For preterm nutrition
496.	Sp	Human Milk fortifier	Sachets	For preterm nutrition

**30. Medicines for Bone and Joints**

	Level	Medicine	Dosage Form and Strength	Notes
497.	S,T	Alendronate	Tablet: 35mg, 40mg, 70mg	For treatment osteoporosis in menopause
498.	S,T	Zoledronate	Injection: 4mg	